[{"Abstract":"<b>Purpose:<\/b> Platinum derivatives are widely used for treating a variety of solid tumours. Besides its direct cytotoxic action, Platinum derivatives play an important role in antitumor immune response, mainly by its inherent capacity to induce immunogenic cell death. Induction of apoptosis using novel therapeutics can be considered a key therapeutic strategy for preventing recurrence and metastasis in cancer patients. Bioplatin is an oral, nano platinum-based compound manufactured using patented innovative processing, based on green technology with an aim of retaining its anti-cancer properties while at the same time reducing its dose limiting toxicities. This compound has demonstrated the property of inducing apoptosis in cancer cells by preventing DNA replication. Since Bioplatin is developed with an aim of arresting disease progression and improving progression-free survival \/disease-free survival its administration is expected to be for a longer duration hence its oral dosing and good tolerability are of utmost importance.<br \/><b>Methods:<\/b> The present study, Phase-I multicentric clinical trial (CTRI\/2017\/06\/008778) was conducted. with an aim of determining the maximum tolerated dose, safety, tolerability and effect on Quality-of-life (QoL) Bioplatin was administered orally for 21 consecutive days to advanced-stage cancer patients of solid tumours who were not responding to any conventional anticancer therapy. Dose escalation was carried out to determine the Maximum Tolerated Dose (MTD).<br \/><b>Results:<\/b> A total of 14 patients received Bioplatin at 4 dose levels, 10 mg, 20 mg, 40 mg, and 60 mg Cohort. The mean progression-free survival (PFS) was 40.25 &#177; 13.47 days. The highest mean PFS of 50.67 &#177; 6.66 days was observed in the 40 mg Cohort. The mean PFS was 37.67 &#177; 16.74 days in 60 mg cohort. Analysis of QoLusing FACT-G showed improvement in QoL (FACT-G) in the 60 mg cohort as compared to Day 1 (<i>p<\/i>&#60;0.05). No dose-limiting toxicity was reported.<br \/><b>Conclusion:<\/b> Considering that Bioplatin can be administered orally, its tolerability, and its property to delay tumor growth, we propose that it can be used for the treatment of patients with platinum-sensitive tumours. Bioplatin has the potential as an orally consumable immunotherapy agent for longer duration. It is expected to increase disease-free survival (DFS) post-surgery \/chemotherapy or as maintenance therapy with other agents in advanced stages patients of platinum-sensitive tumours for improving Quality of life and increasing survival .The findings of the study warrant further clinical evaluation.<b><\/b>","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Solid tumors,Bioplatin,oral chemotherapy,platinum derivatives,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><i>Yogesh Bendale<\/i><\/presenter>, <presenter><i>Vikram Gota<\/i><\/presenter>, <presenter><i>Rajnish Nagarkar<\/i><\/presenter>, <presenter><u><i>Eeshani Bendale<\/i><\/u><\/presenter>, <presenter><i>Nandinee Khot<\/i><\/presenter>, <presenter><i>Surendra Nagre<\/i><\/presenter>, <presenter><i>Avinash Kadam<\/i><\/presenter>. Rasayu Cancer Clinic, Pune, India, Tata Memorial Centre(TMC),Advanced Centre for Treatment, Education and Research in Cancer (ACTREC), Navi Mumbai, India, HCG Manvata Cancer Centre, Nashik, India, Rasayani Biologics Private Limited, Pune, India","CSlideId":"","ControlKey":"e945099f-095d-40c7-b1de-5a68f735b72d","ControlNumber":"8880","DisclosureBlock":"&nbsp;<b>Y. Bendale, <\/b> None..<br><b>V. Gota, <\/b> None..<br><b>R. Nagarkar, <\/b> None..<br><b>N. Khot, <\/b> None..<br><b>S. Nagre, <\/b> None..<br><b>A. Kadam, <\/b> None.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10307","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"1","PosterboardNumber":"1","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT169","PresenterBiography":null,"PresenterDisplayName":"Eeshani Bendale, Unknown","PresenterKey":"2abd993d-035e-4eb1-bd06-2dddafe556c6","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT169. Bioplatin (NTPX-07) as an oral nano platinum in patients of advanced stage malignancy: Outcomes of a phase I clinical trial","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"732","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Bioplatin (NTPX-07) as an oral nano platinum in patients of advanced stage malignancy: Outcomes of a phase I clinical trial","Topics":null,"cSlideId":""},{"Abstract":"A novel approach for cancer therapy was developed, comprising of magnetic multicore iron oxide nanoparticles (SaNPs) and alternating magnetic field (AMF) application. SaNPs are administered IV to the patient and accumulate in tumors through the enhanced permeability and retention (EPR) effect. The patient then undergoes regional AMF application (300kHz) that is converted to thermal energy, inducing sub-ablative hyperthermic cancer cell death. Based on extensive pre-clinical testing, treatment was proven safe and biocompatible in animal models without any associated toxicities. Efficacy studies in a murine metastatic cancer model, demonstrated the ability to reduce the number and size of metastatic lesions.<br \/><b>Methods:<\/b> A First-in-Human open label dose escalation study was designed to evaluate the feasibility and safety of treatment in patients (n=18) with advanced metastatic solid tumors. A secondary objective was to evaluate initial efficacy signs. Eligibility criteria included patients with a life expectancy of at least 30 days with measurable disease according to RECIST 1.1. The patients underwent toxicity analysis and MRI scans without contrast media before (baseline), after treatment, and at the end of the follow-up period of 1 month. Vital signs were monitored before, during, and after treatment. Measurements included ECG, oral and body surface temperatures, blood pressure, heart rate, and oxygen saturation.<br \/><b>Results:<\/b> 3 patients were enrolled in the first cohort that received a single SaNP injection of 10% (first dose level) without AMF. No systemic toxicity was observed. 7 patients were then enrolled and SaNP was administered at the same dose followed by AMF irradiation (first dose level of 40%) of the torso area, conducted for two intervals of 5 min. each. SaNP administration procedures were successful in all cases whereas, 3 patients succeeded to complete the full treatment in accordance to the study protocol. During AMF exposure, the patients were covered with a cooling blanket and temperatures were monitored using fiber-optic sensors. There were no significant temperature deviations beside one patient, where a rise in oral temperature was noted due to the presence of dental implants which heated up. In all patients there were no significant differences in any of the vital signs post-injection nor before or after AMF except for one patient, for whom increased heart rate was observed during irradiation, returning to baseline thereafter. No treatment-related abnormal clinical pathology or urinalysis results were identified. Some fluctuations were observed, attributed to the disease stage. Although tumor response was not expected at the first dose levels, MRI and CT results for one patient showed a reduction in a breast tumor and in another patient, stable disease was reported.<br \/><b>Conclusion: <\/b> SaNP administration either alone or followed by AMF application was not associated with any significant adverse reactions, and no clinical or humoral toxicity was observed at initial doses of 10% SaNP and 40% AMF.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Nanoparticle,Hyperthermia,Solid tumors,Metastatic tumors,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Sarah Kraus<\/i><\/u><\/presenter>, <presenter><i>Cheri Tal<\/i><\/presenter>, <presenter><i>Boaz Shalev<\/i><\/presenter>, <presenter><i>Moshe Eltanani<\/i><\/presenter>, <presenter><i>Pazit Rukenstein<\/i><\/presenter>, <presenter><i>Shir Arbib<\/i><\/presenter>, <presenter><i>Michal Eck<\/i><\/presenter>, <presenter><i>Raz Khandadash<\/i><\/presenter>, <presenter><i>Shaul Atar<\/i><\/presenter>, <presenter><i>Arnoldo Cyjon<\/i><\/presenter>, <presenter><i>Ofer Shalev<\/i><\/presenter>. NEW PHASE , LTD., Petah Tikva, Israel, Galilee Medical Center, Nahariya, Israel, Shamir Medical Center, Zerifim, Israel","CSlideId":"","ControlKey":"d7507f30-d2a8-48dc-9280-0caa49f9c2c4","ControlNumber":"8918","DisclosureBlock":"&nbsp;<b>S. Kraus, <\/b> None..<br><b>C. Tal, <\/b> None..<br><b>B. Shalev, <\/b> None..<br><b>M. Eltanani, <\/b> None..<br><b>P. Rukenstein, <\/b> None..<br><b>S. Arbib, <\/b> None..<br><b>M. Eck, <\/b> None..<br><b>R. Khandadash, <\/b> None..<br><b>S. Atar, <\/b> None..<br><b>A. Cyjon, <\/b> None..<br><b>O. Shalev, <\/b> None.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10308","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"2","PosterboardNumber":"2","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT170","PresenterBiography":null,"PresenterDisplayName":"Sarah Kraus, MBA;PhD","PresenterKey":"b403f50d-d53a-4d7a-8841-93f3900489e2","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT170. Initial safety and feasibility results from a first-in-human clinical trial evaluating a novel magnetic hyperthermia approach for the treatment of metastatic solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"732","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Initial safety and feasibility results from a first-in-human clinical trial evaluating a novel magnetic hyperthermia approach for the treatment of metastatic solid tumors","Topics":null,"cSlideId":""},{"Abstract":"M4076 is a potent and selective oral inhibitor of ataxia&#8209;telangiectasia mutated (ATM), a key kinase of the DNA damage response (DDR) involved in double-strand break repair. Preclinically, M4076 when combined with DNA damage&#8209;inducing therapy or other DDR inhibitors caused unrestricted cell cycle progression and DNA damage accumulation, resulting in tumor cell death.<br \/>Part 1A of this ongoing open&#8209;label study (NCT04882917) evaluated the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and maximum tolerated dose (MTD) of M4076 monotherapy in patients (pts) with advanced solid tumors. Dose escalation was guided by safety, along with Bayesian analysis, PK, and PD.<br \/>In total, 22 pts received M4076 at 4 different dose levels (100-400 mg once daily [QD]); 21 pts (95.5%) discontinued treatment (progressive disease: 11 [50%], adverse events [AEs]: 5 [22.7%]). Dose-limiting toxicities (DLTs) were reported in 4 pts. Overall, 6 pts had &#8805;1 treatment&#8209;related AE (TRAE) of Grade &#8805;3 (including one Grade 4 hypersensitivity). The most common TRAEs were rash and anemia (Table 1). MTD was determined at 300 mg QD. As per preliminary PK across cohorts, M4076 was rapidly absorbed with median T<sub>max<\/sub> ~0.5-2 h and mean elimination half&#8209;life (t<sub>1\/2<\/sub>) ~2-10 h; exposure increased in a dose&#8209;related manner, with minimum accumulation after multiple QD doses. At &#8805;200 mg QD, unbound steady state plasma concentration exceeded <i>in vivo<\/i> pCHK2 IC<sub>90<\/sub> throughout the dosing interval. PD evaluation was based on the modulation of &#947;-H2AX (a direct ATM target) in <i>ex vivo<\/i> bleomycin stimulated CD45+ lymphocytes, by flow cytometry. Preliminary analyses showed a trend of reduction of &#947;&#8209;H2AX levels from day 1 to day 2, reaching 80-100% of target inhibition on day 2 with the dose range 100-400 mg QD.<br \/>The MTD of M4076 was determined, and target exposure and engagement were achieved without significant hematological toxicity. Future investigations on M4076 as combination therapy are planned.<table border=\"1\"  cellpadding=\"1\" class=\"DisplayTable\" id=\"{1F3ED90A-B6E9-41ED-9CFD-82EE79F0FA04}\"><caption>Table 1: Safety overview<\/caption><tr><td rowspan=\"1\" colspan=\"1\"><b>Dose<br><\/b>(Safety set)<\/td><td rowspan=\"1\" colspan=\"1\"><b>Patients with TRAEs<br><\/b><b>(Grade &#8805;3)<\/b><\/td><td rowspan=\"1\" colspan=\"1\"><b>DLT analysis set<\/b><br>(Patients with &#8805;80% of the planned dose or DLT per investigator)<\/td><td rowspan=\"1\" colspan=\"1\"><b>DLT<\/b><\/td><td rowspan=\"1\" colspan=\"1\"><b>DLT AE terms<\/b><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">100 mg<br>(n = 2)<\/td><td rowspan=\"1\" colspan=\"1\">No<\/td><td rowspan=\"1\" colspan=\"1\">n = 2<\/td><td rowspan=\"1\" colspan=\"1\">No<\/td><td rowspan=\"1\" colspan=\"1\">NA<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">200 mg<br>(n = 7)<\/td><td rowspan=\"1\" colspan=\"1\">n = 1 (decreased lymphocyte count, maculo&#8209;papular rash)<\/td><td rowspan=\"1\" colspan=\"1\">n = 5<\/td><td rowspan=\"1\" colspan=\"1\">Yes<br>(n = 1)<\/td><td rowspan=\"1\" colspan=\"1\">Grade 3 maculo-papular rash (TRAE, required drug withdrawal; resolved)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">300 mg<br>(n = 9)<\/td><td rowspan=\"1\" colspan=\"1\">n = 3 (anemia, spontaneous bacterial peritonitis)<\/td><td rowspan=\"1\" colspan=\"1\">n = 7<\/td><td rowspan=\"1\" colspan=\"1\">Yes<br>(n = 1)<\/td><td rowspan=\"1\" colspan=\"1\">Grade 1 maculo-papular rash; Grade 2 fever (TRAEs, required treatment discontinuation; resolved)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">400 mg<br>(n = 4)<\/td><td rowspan=\"1\" colspan=\"1\">n = 2 (nausea, maculo&#8209;papular rash, hypersensitivity)<\/td><td rowspan=\"1\" colspan=\"1\">n = 4<\/td><td rowspan=\"1\" colspan=\"1\">Yes<br>(n = 2)<\/td><td rowspan=\"1\" colspan=\"1\">Grade 3 maculo-papular rash (TRAEs, required dose reduction\/interruption and\/or concomitant medication; resolved)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"5\">MedDRA version 23.0, NCI&#8209;CTCAE version 5.0. Data cutoff: 2 Nov 2022<br>AE, adverse event; DLT, dose-limiting toxicity; NA, not applicable; TRAE, treatment-related AE<\/td><\/tr><\/table>","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"ATM,DNA double-strand break repair genes,DNA repair inhibition,M4076,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Lillian L. Siu<\/i><\/u><\/presenter>, <presenter><i>Timothy A. Yap<\/i><\/presenter>, <presenter><i>Sofia Genta<\/i><\/presenter>, <presenter><i>Gregory Pennock<\/i><\/presenter>, <presenter><i>Christine Hicking<\/i><\/presenter>, <presenter><i>Xiaoli You<\/i><\/presenter>, <presenter><i>Jatinder K. Mukker<\/i><\/presenter>, <presenter><i>Giuseppe Locatelli<\/i><\/presenter>, <presenter><i>Anthony W. Tolcher<\/i><\/presenter>. University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada, University of Texas MD Anderson Cancer Center, Houston, TX, EMD Serono, Inc., Orlando, FL, the healthcare business of Merck KGaA, Darmstadt, Germany, EMD Serono, Billerica, MA, New Experimental Therapeutics (NEXT), San Antonio, TX","CSlideId":"","ControlKey":"98f706da-1740-4178-8c72-1c36672c685e","ControlNumber":"8945","DisclosureBlock":"<b>&nbsp;L. L. Siu, <\/b> <br><b>AstraZeneca, Celgene, GlaxoSmithKline, the healthcare business of Merck KGaA, Pfizer, Darmstadt, Germany, Symphogen<\/b> Other, Personal fees for advisory boards and sponsorship\/funding (clinical trial support for institution). <br><b>Arvinas, Daiichi Sanyko, Janpix, Morphosys, Navire, Oncorus, Relay, Roche, Rubius, Seattle Genetics, Tessa, Voronoi<\/b> Other, Personal fees for advisory boards. <br><b>AbbVie, Amgen, Astellas, Avid, Bayer, Boerhinger Ingelheim, Intensity Therapeutics, Karyopharm, Bristol-Myers Squibb, Mirati Therapeutics, Novartis, Roche\/Genentech, Shattucks<\/b> Other, Sponsorship\/funding (clinical trial support for institution). <br><b>Treadwell Therapeutics<\/b> Other, Spouse is a co-founder; reports ownership interest. <br><b>Agios<\/b> Other, Spouse owns stock. <br><b>T. A. Yap, <\/b> <br><b>University of Texas MD Anderson Cancer Center, which has a commercial interest in DDR and other inhibitors (IACS30380\/ART0380 was licensed to Artios)<\/b> Employment. <br><b>BioNTech, Blueprint, Constellation, Cyteir, Eli Lilly, Forbius, Genentech, Haihe, Ionis, Ipsen, Jounce, Karyopharm, KSQ, Kyowa, Mirati, Novartis, Ribon Therapeutics, Regeneron, Rubius, Sanofi<\/b> Other, Grant\/research support. <br><b>Scholar Rock, Seattle Genetics, Tesaro, Vivace, Zenith<\/b> Other, Grant\/research support. <br><b>Acrivon, AstraZeneca, Artios, Bayer, Beigene, Bristol Myers Squibb, Clovis, EMD Serono, F-Star, GSK, ImmuneSensor, Merck & Co., Pfizer, Repare<\/b> Other, Received grant\/research support and consulted. <br><b>AbbVie, Adagene, Almac, Aduro, Amphista, Athena, Atrin, Avoro, Axiom, Baptist Health Systems, Boxer, C4 Therapeutics, Calithera, Cancer Research UK, Cybrexa, Diffusion, Genmab, Glenmark, GLG<\/b> Other, Consulted. <br><b>Globe Life Sciences, Guidepoint, Idience, Ignyta, I-Mab, Institut Gustave Roussy, Intellisphere, Jansen, Kyn, MEI pharma, Mereo, Natera, Nexys, Novocure, OHSU, OncoSec, Ono Pharma, Pegascy, PER<\/b> Other, Consulted. <br><b>Piper-Sandler, Prolynx, resTORbio, Roche, Schrodinger, Theragnostics, Varian, Versant, Vibliome, Xinthera, Zai Labs, ZielBio<\/b> Other, Consulted. <br><b>Seagen<\/b> Stock.<br><b>S. Genta, <\/b> None.&nbsp;<br><b>G. Pennock, <\/b> <br><b>EMD Serono, Billerica, MA, USA<\/b> Employment, Stock. <br><b>C. Hicking, <\/b> <br><b>the healthcare business of Merck KGaA, Darmstadt, Germany<\/b> Employment, Stock. <br><b>X. You, <\/b> <br><b>EMD Serono, Billerica, MA, USA<\/b> Employment, Stock. <br><b>J. K. Mukker, <\/b> <br><b>EMD Serono, Billerica, MA, USA<\/b> Employment, Stock. <br><b>G. Locatelli, <\/b> <br><b>the healthcare business of Merck KGaA, Darmstadt, Germany<\/b> Employment. <br><b>A. W. Tolcher, <\/b> <br><b>New Experimental Therapeutics, LLC d\/b\/a NEXT Oncology<\/b> Other, All fee for consulting and advisory boards memberships are paid to New Experimental Therapeutics, LLC d\/b\/a NEXT Oncology of which he is President and Founder. <br><b>ADAGENE, Inc, ARO BIOTHERAPEUTICS, BIOINVENT, Boeringer Ingelheim International GmbH, Bright Peak Therapeutics, Deka Biosciences, Eleven Bio, ELUCIDA, EMD Serono\/the healthcare business of Merck KGaA<\/b> Other, Advisory board. <br><b>Hiber Cell Inc, Ikena Oncology, IMMUNOME, Janssen Global Services LLC, NBE THERAPEUTICS, Pelican, Pieris Pharma, PYXIS Oncology, Senti Biosciences, Vincerx, ZielBio Inc<\/b> Other, Advisory board. <br><b>ABBVIE, Inc., Aclaris Therapeutics, AGENUS, Inc, ASANA BIOSCIENCES, ASCENTAGE, AxImmune, Bayer, Blu Print Oncology, Daiichi Sankyo Inc, GILDE HEALTHCARE PARTNERS, HBM PARTNERS, IDEA Pharma<\/b> Other, Consultant. <br><b>Immuneering, Immunomet Therapeutics, Inc., Impact Therapeutics US Inc, Karma Oncology B.V., Kirilys Therapeutics Inc, Lengo Therapeutics Inc, Link Immunotherapeutics, Mekanistic Therapeutics<\/b> Other, Consultant. <br><b>Menarini Ricerche, Mersana, NANOBIOTIX, Novo Nordisk Inc, NervianoMedical Sciences S.r.l. (NMS), Nurix Therapeutics, Ocellaris Pharma Inc & Eli Lilly, Partner Therapeutics, Pfizer Inc, PIERRE FABRE<\/b> Other, Consultant. <br><b>Qualigen Therapeutics, RYVU THERAPEUTICS, Seattle Genetics, SK Life Science, SOTIO Biotechnology Co., Spirea Limited Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd<\/b> Other, Consultant. <br><b>Transcenta Therapeutics Inc., Transgene, Trillium Therapeutics Inc., Verastem Oncology, VRISE Therapeutics Inc, Zentalis Pharmaceuticals<\/b> Other, Consultant. <br><b>Roche<\/b> Other, Advisory board and consultant. <br><b>Zymeworks Biopharmaceuticals Inc, MIRATI<\/b> Other, Advisory board.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10309","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"3","PosterboardNumber":"3","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT171","PresenterBiography":null,"PresenterDisplayName":"Lillian Siu, MD","PresenterKey":"7501fbfb-af2e-4490-8f84-1f5ea25999e8","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT171. A first-in-human phase I study of the ATM inhibitor M4076 in patients with advanced solid tumors (DDRiver Solid Tumors 410): Part 1A results","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"732","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A first-in-human phase I study of the ATM inhibitor M4076 in patients with advanced solid tumors (DDRiver Solid Tumors 410): Part 1A results","Topics":null,"cSlideId":""},{"Abstract":"<b>Introduction:<\/b> PRT1419, a selective inhibitor of MCL-1, has demonstrated preclinical activity in solid tumors and hematologic malignancies. We report the results of a phase 1, open-label, multicenter, dose-escalation study of PRT1419 in pts with advanced\/metastatic solid tumors (NCT04837677).<br \/><b>Methods:<\/b> Adults with select advanced\/metastatic solid tumors were enrolled. Key inclusion criteria were absolute neutrophil count &#62;1.0, platelets &#62;75, hemoglobin &#62;9, and left ventricular ejection fraction &#8805;50%. Key exclusion criteria were active central nervous system malignancy, significant cardiac disease, and concurrent strong CYP2C8 inhibitors. The study employed a 3+3 dose escalation design. PRT1419 was administered as a once-weekly (QW) infusion. Primary outcome measures were to evaluate dose-limiting toxicities (DLT) and establish the maximum tolerated dose and recommended phase 2 dose (RP2D). Secondary outcome measures included safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity.<br \/><b>Results:<\/b> Pts with melanoma (n=8), sarcoma (n=5), esophageal (n=4), cervical (n=3), head and neck (n=3), non-small cell lung, small cell lung, and triple-negative breast cancer (all n=1) were enrolled. Median age was 59.5 (range, 32-78) years, 61.5% pts were female, and median prior lines of systemic therapy was 3 (range, 1-8). Overall, 26 pts received &#8805;1 dose of PRT1419 (20 mg\/m<sup>2<\/sup> [n=4], 40 mg\/m<sup>2<\/sup> [n=4], 80 mg\/m<sup>2<\/sup> [n=15], and 120 mg\/m<sup>2<\/sup> [n=3]). Most pts (84.6%) discontinued treatment (primary reason: progressive disease, 72.7%). No DLTs, adverse events (AEs) of increased troponin or heart failure, or grade 5 (fatal) AEs were observed. Any grade treatment-related AEs (TRAE) occurred in 80.8% pts; the most common were nausea (50.0%), diarrhea (46.2%), and vomiting (46.2%). Grade 3\/4 TRAEs occurred in 11.5% pts; the most common was neutropenia (11.5%), which was dose related. Due to neutropenia observed at doses &#62;80 mg\/m<sup>2<\/sup>, further dose escalation was not investigated. BAX and caspase 3 activation in peripheral blood monocytes was observed at 80 mg\/m<sup>2<\/sup> and 120 mg\/m<sup>2<\/sup>. Stable disease was the best response observed. Tumor shrinkage was seen in 1 pt with melanoma (10% reduction) and 1 pt with lung cancer (4% reduction) but did not meet the criteria for partial response. At Week 3, mean clearance was 12.6 L\/hr and mean half-life was 2.5 hrs; no PRT1419 accumulation was seen with QW dosing.<br \/><b>Conclusions:<\/b> PRT1419 demonstrated acceptable safety and tolerability in pts with advanced\/metastatic solid tumors, with primary TRAEs of neutropenia, nausea, diarrhea, and vomiting. No cardiac toxicity was observed. BAX and caspase 3 activation was observed, suggesting potentially successful MCL-1 inhibition. Investigation of PRT1419 in pts with hematologic malignancy in a separate study is ongoing (NCT05107856).","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Mcl-1,Phase I,Solid tumors,Cancer therapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Gerald Falchook<\/i><\/u><\/presenter>, <presenter><i>Manish Patel<\/i><\/presenter>, <presenter><i>Meredith McKean<\/i><\/presenter>, <presenter><i>Alexander Philipovskiy<\/i><\/presenter>, <presenter><i>Rachel Chiaverelli<\/i><\/presenter>, <presenter><i>William Sun<\/i><\/presenter>, <presenter><i>Michael Fossler<\/i><\/presenter>, <presenter><i>William Novotny<\/i><\/presenter>, <presenter><i>Michael Kurman<\/i><\/presenter>, <presenter><i>Sarah Rowe<\/i><\/presenter>, <presenter><i>Deborah Hunter<\/i><\/presenter>, <presenter><i>Mohammed Milhem<\/i><\/presenter>. Sarah Cannon Research Institute at HealthONE, Denver, CO, Florida Cancer Specialists\/Sarah Cannon Research Institute, Sarasota, FL, Sarah Cannon Research Institute\/Tennessee Oncology, PLLC., Nashville, TN, Florida Cancer Specialists\/Sarah Cannon Research Institute, Lake Mary, FL, Prelude Therapeutics Incorporated, Wilmington, DE, University of Iowa, Iowa City, IA","CSlideId":"","ControlKey":"9de93cd8-ba48-46d5-9aa5-9e724fffcd13","ControlNumber":"9353","DisclosureBlock":"<b>&nbsp;G. Falchook, <\/b> <br><b>Wolters Kluwer<\/b> Other, Royalties. <br><b>AbbVie<\/b> Other, Advisory Role. <br><b>Silicon<\/b> Other, Advisory Role. <br><b>Navire<\/b> Other, Advisory Role. <br><b>Turning Point<\/b> Other, Advisory Role. <br><b>Predicine<\/b> Other, Advisory Role. <br><b>Inspirna<\/b> Other, Advisory Role. <br><b>Regeneron<\/b> Other, Advisory Role. <br><b>Jubilant<\/b> Other, Advisory Role. <br><b>BostonGene<\/b> Other, Advisory Role. <br><b>Amgen<\/b> Travel. <br><b>Sarah Cannon Research Institute<\/b> Employment, Travel. <br><b>Synthorx\/Sanofi<\/b> Travel. <br><b>3-V Biosciences<\/b> Other, Principal Investigator. <br><b>Abbisko<\/b> Other, Principal Investigator. <br><b>Abbvie<\/b> Other, Principal Investigator. <br><b>ABL Bio,<\/b> Other, Principal Investigator. <br><b>ADC Therapeutics<\/b> Other, Principal Investigator. <br><b>Accutar<\/b> Other, Principal Investigator. <br><b>Agenus<\/b> Other, Principal Investigator. <br><b>M. Patel, <\/b> <br><b>ION Pharma<\/b> Other, Leadership. <br><b>Janssen Oncology<\/b> Other, Honoraria. <br><b>Acerta Pharma<\/b> Other, Research Funding. <br><b>ADC Therapeutics<\/b> Other, Research Funding. <br><b>Agenus<\/b> Other, Research Funding. <br><b>Aileron Therapeutics<\/b> Other, Research Funding. <br><b>AstraZeneca<\/b> Other, Research Funding. <br><b>BioNTech AG<\/b> Other, Research Funding. <br><b>Boehringer Ingelheim<\/b> Other, Research Funding. <br><b>Celgene<\/b> Other, Research Funding. <br><b>CicloMed<\/b> Other, Research Funding. <br><b>Clovis Oncology<\/b> Other, Research Funding. <br><b>Cyteir Therapeutics<\/b> Other, Research Funding. <br><b>Daiichi Sankyo<\/b> Other, Research Funding. <br><b>Lilly<\/b> Other, Research Funding. <br><b>Evelo Therapeutics<\/b> Other, Research Funding. <br><b>Genentech\/Roche<\/b> Other, Research Funding. <br><b>Gilead Sciences<\/b> Other, Research Funding. <br><b>GlaxoSmithKline<\/b> Other, Research Funding. <br><b>H3 Biomedicine<\/b> Other, Research Funding. <br><b>M. McKean, <\/b> <br><b>Prelude Therapeutics<\/b> Other, Funding for study. <br><b>Aadi Biosciences<\/b> Grant\/Contract. <br><b>Accutar Biotechnology<\/b> Grant\/Contract. <br><b>Alpine Immune Sciences<\/b> Grant\/Contract. <br><b>Arcus Biosciences<\/b> Grant\/Contract. <br><b>Arvinas<\/b> Grant\/Contract. <br><b>Ascentage Pharma Group<\/b> Grant\/Contract. <br><b>Astellas<\/b> Grant\/Contract. <br><b>Bayer<\/b> Grant\/Contract. <br><b>Bicycle Therapeutics<\/b> Grant\/Contract. <br><b>BioMed Valley Discoveries<\/b> Grant\/Contract. <br><b>BioNTech<\/b> Grant\/Contract. <br><b>Dragonfly Therapeutics<\/b> Grant\/Contract. <br><b>Astellas Pharma<\/b> Other, Consulting. <br><b>AstraZeneca<\/b> Other, Consulting. <br><b>BicycleTx Limited<\/b> Other, Consulting. <br><b>Castle Biosciences<\/b> Other, Consulting. <br><b>Eisai<\/b> Other, Consulting. <br><b>Ideaya Biosciences<\/b> Other, Consulting. <br><b>iTeos<\/b> Other, Consulting.<br><b>A. Philipovskiy, <\/b> None.&nbsp;<br><b>R. Chiaverelli, <\/b> <br><b>Prelude Therapeutics<\/b> Employment, Stock. <br><b>W. Sun, <\/b> <br><b>Prelude Therapeutics<\/b> Employment, Stock. <br><b>M. Fossler, <\/b> <br><b>Prelude Therapeutics<\/b> Other, Consulting. <br><b>American College of Clinical Pharmacology<\/b> Other, Leadership. <br><b>Trevena, Inc<\/b> Stock. <br><b>W. Novotny, <\/b> <br><b>Prelude Therapeutics<\/b> Employment, Stock, Travel, Other, Advisory Board. <br><b>M. Kurman, <\/b> <br><b>Prelude Therapeutics<\/b> Other, Consulting. <br><b>S. Rowe, <\/b> <br><b>Prelude Therapeutics, Inc.<\/b> Employment. <br><b>D. Hunter, <\/b> <br><b>Prelude Therapeutics<\/b> Other, Consulting. <br><b>M. Milhem, <\/b> <br><b>Syneos<\/b> Other, Consulting. <br><b>Exicure<\/b> Other, Consulting. <br><b>Novartis<\/b> Other, Consulting. <br><b>Immunocore<\/b> Other, Consulting. <br><b>Biontech<\/b> Other, Consulting. <br><b>Blueprints Medicine<\/b> Other, Consulting. <br><b>Amgen<\/b> Other, Consulting. <br><b>Array<\/b> Other, Consulting. <br><b>Trieza<\/b> Other, Consulting.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10310","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"4","PosterboardNumber":"4","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT172","PresenterBiography":null,"PresenterDisplayName":"GERALD FALCHOOK","PresenterKey":"d803cb44-151a-419c-8e64-bb941ada6e2d","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT172. A phase 1, open-label, dose-escalation study of PRT1419, a selective induced myeloid leukemia cell differentiation protein (MCL-1) inhibitor, in patients (pts) with advanced\/metastatic solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"732","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A phase 1, open-label, dose-escalation study of PRT1419, a selective induced myeloid leukemia cell differentiation protein (MCL-1) inhibitor, in patients (pts) with advanced\/metastatic solid tumors","Topics":null,"cSlideId":""},{"Abstract":"<b>Background<\/b>: CDK9 is a key regulator of transcription elongation and recent studies suggest selective CDK9 inhibition may be a promising approach to treat &#8220;transcription-addicted&#8221; cancers that are dependent on oncogenic drivers with a short half-life. We report phase 1 dose-escalation results from an ongoing open-label study of PRT2527 (NCT05159518), a potent and highly selective CDK9 inhibitor, in pts with advanced solid tumors.<br \/><b>Methods<\/b>: Key inclusion criteria include pts aged &#8805;18 years; selected sarcomas, castrate-resistant prostate cancer (CRPC), HR+\/HER2- breast cancer, non-small cell lung cancer, or <i>MYC<\/i>-amplified solid tumors; received prior therapy; measurable disease (evaluable for CRPC); ECOG PS &#8804;1; and adequate organ function. Central nervous system disease is allowed if stable and adequately controlled. Pts received a once-weekly (QW; 21-day cycle) infusion of PRT2527 (3, 6, and 12 mg\/m<sup>2<\/sup> QW, n=3 pts per dose level using a Bayesian optimal interval dose escalation design) until intolerance, progression, death, or withdrawal. Primary objectives were to evaluate dose-limiting toxicities (DLT), establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of PRT2527. Secondary objectives included safety and tolerability, pharmacokinetics, and antitumor activity.<br \/><b>Results<\/b>: At data cutoff (30 September 2022), 9 pts (CRPC, n=5; breast cancer, n=2; sarcoma, n=2) were treated in the first 3 dose levels of dose escalation. Median age was 64 (range, 57-73) years and 56% of pts were male. No DLTs were observed, the MTD was not reached, and evaluation of the RP2D is ongoing. Overall, 89% of pts have discontinued therapy (75% due to progressive disease); no discontinuations or dose reductions due to adverse events (AEs) and no deaths were reported. One pt on 12 mg\/m<sup>2<\/sup> QW had a dose interruption due to grade 2 myalgia and arthralgia; both events were considered related to study drug. All-cause, any grade AEs occurred in 89% of pts, most commonly nausea (44%), decreased appetite (33%), diarrhea (33%), and vomiting (33%). All-cause grade 3\/4 AEs occurred in 22% of pts, including anemia (11%) and hyperglycemia (11%); both were unrelated to study treatment. One serious AE unrelated to treatment was reported (pneumothorax). Dose-dependent inhibition of CDK9 transcriptional targets was observed. A mean decrease of 88% (SD, 2.4%; n=3) in <i>MCL1<\/i> and <i>MYC<\/i> mRNA was achieved 2 hours post-infusion of the 12 mg\/m<sup>2<\/sup> dose; by 4 hours post-infusion, expression levels had rebounded to 50% (SD, 2.7%; n=3; <i>MYC<\/i>) and 78% (SD, 6.4%; n=3; <i>MCL1<\/i>) inhibition.<br \/><b>Conclusions<\/b>: PRT2527 is generally well tolerated in adults with advanced solid tumors. Updated data (including efficacy) will be presented.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"CDK inhibitor,Cancer therapy,Solid tumors,Phase I,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Jason T. Henry<\/i><\/u><\/presenter>, <presenter><i>Douglas Orr<\/i><\/presenter>, <presenter><i>Atrayee Basu-Mallick<\/i><\/presenter>, <presenter><i>Alex Spira<\/i><\/presenter>, <presenter><i>Christine Lihou<\/i><\/presenter>, <presenter><i>Neelesh Sharma<\/i><\/presenter>, <presenter><i>Peggy Scherle<\/i><\/presenter>, <presenter><i>Rachel Chiaverelli<\/i><\/presenter>, <presenter><i>Manish R. Patel<\/i><\/presenter>. Sarah Cannon Research Institute at HealthOne, Denver, CO, Mary Crowley Cancer Research, Dallas, TX, Thomas Jefferson University Hospital, Philadelphia, PA, Virginia Cancer Specialists Research Institute\/NEXT Oncology Virginia, Fairfax, VA, Prelude Therapeutics Incorporated, Wilmington, DE, Florida Cancer Specialists\/Sarah Cannon Research Institute, Sarasota, FL","CSlideId":"","ControlKey":"cf3f7331-fefa-43ca-8327-3dcbac99c8be","ControlNumber":"9409","DisclosureBlock":"<b>&nbsp;J. T. Henry, <\/b> <br><b>Sarah Cannon Research Institute<\/b> Travel. <br><b>HCA<\/b> Stock. <br><b>Abbiscko Therapeutics<\/b> Other, Primary Investigator. <br><b>ABl bio<\/b> Other, Primary Investigator. <br><b>Accutar biotech<\/b> Other, Primary Investigator. <br><b>Agenus<\/b> Other, Primary Investigator. <br><b>Aileron Therapeutics<\/b> Other, Primary Investigator. <br><b>Amgen inc<\/b> Other, Primary Investigator. <br><b>Artios<\/b> Other, Primary Investigator. <br><b>Astrazenaca<\/b> Other, Primary Investigator. <br><b>Bicycle therapeutics<\/b> Other, Primary Investigator. <br><b>BioAlta<\/b> Other, Primary Investigator. <br><b>BioInvent pharma<\/b> Other, Primary Investigator. <br><b>Biosplice therapeutics<\/b> Other, Primary Investigator. <br><b>Black diamond therapeutics<\/b> Other, Primary Investigator. <br><b>Boehringer Ingelheim<\/b> Other, Primary Investigator. <br><b>Cyteir<\/b> Other, Primary Investigator. <br><b>Daiichi Sankyo<\/b> Other, Primary Investigator. <br><b>Eli Lilly<\/b> Other, Primary Investigator. <br><b>Epizyme<\/b> Other, Primary Investigator.<br><b>D. Orr, <\/b> None.&nbsp;<br><b>A. Basu-Mallick, <\/b> <br><b>Thomas Jefferson University Hospital<\/b> Other, Funding for study.<br><b>A. Spira, <\/b> None.&nbsp;<br><b>C. Lihou, <\/b> <br><b>Prelude Therapeutics<\/b> Employment, Stock. <br><b>N. Sharma, <\/b> <br><b>Bayer<\/b> Employment. <br><b>Prelude Therapeutics<\/b> Employment, Stock. <br><b>P. Scherle, <\/b> <br><b>Prelude Therapeutics<\/b> Employment, Stock. <br><b>R. Chiaverelli, <\/b> <br><b>Prelude Therapeutics<\/b> Employment, Stock. <br><b>M. R. Patel, <\/b> <br><b>ION Pharma<\/b> Other, Leadership. <br><b>Janssen Oncology<\/b> Other, Honoraria. <br><b>Olema Pharmaceuticals<\/b> Other, Advisory Role. <br><b>Acerta Pharma<\/b> Other, Research Funding. <br><b>ADC Therapeutics<\/b> Other, Research Funding. <br><b>Agenus<\/b> Other, Research Funding. <br><b>Aileron Therapeutics<\/b> Other, Research Funding. <br><b>AstraZeneca<\/b> Other, Research Funding. <br><b>BioNTech AG<\/b> Other, Research Funding. <br><b>Boehringer Ingelheim<\/b> Other, Research Funding. <br><b>Celgene<\/b> Other, Research Funding. <br><b>CicloMed<\/b> Other, Research Funding. <br><b>Clovis Oncology<\/b> Other, Research Funding. <br><b>Cyteir Therapeutics<\/b> Other, Research Funding. <br><b>Daiichi Sankyo<\/b> Other, Research Funding. <br><b>Lilly<\/b> Other, Research Funding. <br><b>Evelo Therapeutics<\/b> Other, Research Funding. <br><b>Genentech\/Roche<\/b> Other, Research Funding. <br><b>Gilead Sciences<\/b> Other, Research Funding. <br><b>GlaxoSmithKline<\/b> Other, Research Funding.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10311","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"5","PosterboardNumber":"5","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT173","PresenterBiography":null,"PresenterDisplayName":"Jason Henry, MD","PresenterKey":"4cee953a-6afa-4c02-9666-7b247282d2c0","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT173. A phase 1, open-label, multicenter, dose-escalation study of PRT2527, a cyclin-dependent kinase 9 (CDK9) inhibitor, in adult patients (pts) with advanced solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"732","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A phase 1, open-label, multicenter, dose-escalation study of PRT2527, a cyclin-dependent kinase 9 (CDK9) inhibitor, in adult patients (pts) with advanced solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Background: CD200R1 was identified as a promising immuno-oncology (IO) target from the 23andMe database. Pleiotropic causal variants with opposing effect on risks for cancer and immune diseases, referred to as an IO signature, were observed in 3 components of the CD200R1 pathway.<br \/>23ME-00610 is a first-in-class monoclonal antibody that potently inhibits the CD200R1 immune checkpoint (K<sub>D<\/sub> less than 0.1 nM). The dose escalation portion of the first-in-human, Phase 1\/2a study of 23ME-00610 (NCT05199272) has been completed and we are reporting data for the first time.<br \/>Methods: Eligible patients were alteast 18 years with histologically diagnosed locally advanced (unresectable), or metastatic carcinoma or sarcoma who have progressed on standard therapies with ECOG 0 or 1. Key exclusion criteria included active autoimmune disease requiring immunosuppressive therapy and Grade 3 or above immune-mediated toxicity related to prior immunotherapy that led to discontinuation. Dose escalation consisted of accelerated titration (2 and 6 mg) followed by a 3+3 design (20, 60, 200, 600 and 1400 mg). Up to 12 participants were included in a PKPD backfill cohort at the recommended phase 2 dose (RP2D) or a previously evaluated dose level. Participants received 23ME-00610 intravenously every 3 weeks (Q3W) infused over 30 minutes. The primary objectives of Phase 1 were determination of the maximum tolerated dose (MTD)\/recommended phase 2 dose (RP2D), safety and tolerability. Key secondary and exploratory objectives included pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of 23ME-00610.<br \/>Results: Between January 5<sup>th<\/sup>, 2022 and November 28, 2022, 21 participants (11\/10 male\/female; age range: 21-80 years) were enrolled and received &#8805; 1 dose of 23ME-00610 across the 2 to 1400 mg cohorts (median duration of exposure: 50 days; range:1-231 days). No dose limiting toxicities, treatment related serious adverse events (TRSAEs) or AEs leading to discontinuation were observed. 14\/21 (67%) participants experienced atleast 1 TRAE; the majority were Grade 1 or 2. The most commonly reported TRAEs occurring in atleast 2 participants across all dose levels were headache, fatigue, nausea and pruritis. There was 1 Grade 3 TRAE of increased blood creatinine phosphokinase. Investigator-assessed immune-related AEs including hypothyroidism, pruritis, fatigue and chills were observed at doses 60 mg and above. The PK of 23ME-00610 were dose-proportional at doses 60 mg and above, with a median terminal half-life of ~12 days at 1400 mg. Peripheral saturation of CD200R1 was observed at doses 60 mg and above, as measured by receptor occupancy on T cells and neutrophils, and levels of free soluble CD200R1. Analysis of additional PD data, including cytokines, is ongoing.<br \/>Conclusion: 23ME-00610 demonstrated an acceptable safety and tolerability profile, with favorable PK and peripheral CD200R1 saturation. Increased immune-related AEs were observed at higher, pharmacologically relevant dose levels. Based on Phase 1 data, 1400 mg 23ME-00610 Q3W will be evaluated in Phase 2a.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Immunotherapy,Solid tumors,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Shivaani Kummar<\/i><\/u><\/presenter>, <presenter><i>Albiruni ABDUL RAZAK<\/i><\/presenter>, <presenter><i>Scott Laurie<\/i><\/presenter>, <presenter><i>Sariah Kell<\/i><\/presenter>, <presenter><i>Dylan Glatt<\/i><\/presenter>, <presenter><i>Sophia R. Majeed<\/i><\/presenter>, <presenter><i>Drew Rasco<\/i><\/presenter>. OHSU - Knight Cancer Institute, Portland, OR, Princess Margaret Cancer Centre, Toronto, ON, Canada, The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada, 23andMe, South San Francisco, CA, The START Center for Cancer Care, San Antonio, San Antonio, TX","CSlideId":"","ControlKey":"6116ba7e-2b10-4e90-a970-86863f7dfa44","ControlNumber":"9466","DisclosureBlock":"<b>&nbsp;S. Kummar, <\/b> <br><b>Boehringer Ingelheim<\/b> Other, Consultant and Advisory Board. <br><b>Springworks Therapeutics<\/b> Other, Consultant and Advisory Board. <br><b>Bayer<\/b> Other, Consultant and Advisory Board. <br><b>Genome & Company<\/b> Other, Consultant and Advisory Board. <br><b>Genome Insight<\/b> Other, Consultant and Advisory Board. <br><b>HarbourBiomed<\/b> Other, Consultant and Advisory Board. <br><b>Berg<\/b> Other, Consultant and Advisory Board. <br><b>Oxford Biotherapeutics<\/b> Other, Consultant and Advisory Board. <br><b>Mundibiopharma<\/b> Other, Consultant and Advisory Board. <br><b>Gilead<\/b> Other, Consultant and Advisory Board. <br><b>EcoR1<\/b> Other, Consultant and Advisory Board. <br><b>Mirati<\/b> Other, Consultant and Advisory Board. <br><b>PathomIQ<\/b> Other Business Ownership, Co-Founder. <br><b>Cadila Pharmaceuticals<\/b> Other, Scientific Advisor - Spouse. <br><b>Arxeon<\/b> Other, Co-founder - Spouse. <br><b>A. Abdul razak, <\/b> <br><b>Adaptimune<\/b> Other, Consulting or Advisory Role. <br><b>Bayer<\/b> Other, Consulting or Advisory Role. <br><b>GSK<\/b> Other, Consulting or Advisory Role. <br><b>Medison<\/b> Consulting or Advisory Role. <br><b>Inhibrx<\/b> Other, Consulting or Advisory Role.<br><b>S. Laurie, <\/b> None.&nbsp;<br><b>S. Kell, <\/b> <br><b>23andMe<\/b> Employment, Stock. <br><b>D. Glatt, <\/b> <br><b>23andMe<\/b> Employment, Stock, Stock Option. <br><b>S. R. Majeed, <\/b> <br><b>23andMe<\/b> Employment, Stock, Stock Option. <br><b>Gilead<\/b> Stock.<br><b>D. Rasco, <\/b> None.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10312","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"6","PosterboardNumber":"6","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT174","PresenterBiography":null,"PresenterDisplayName":"Sophia Majeed, Pharm D,PhD","PresenterKey":"5b7466f8-a56a-4ff2-bb46-b307ebde5f01","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT174. First-in-class anti-CD200R1 antibody 23ME-00610 in patients with advanced solid malignancies: Phase 1 results","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"732","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"First-in-class anti-CD200R1 antibody 23ME-00610 in patients with advanced solid malignancies: Phase 1 results","Topics":null,"cSlideId":""},{"Abstract":"<b>Background: <\/b>SHR-A1811 is an ADC comprised of a humanized anti-HER2 monoclonal antibody (trastuzumab), a cleavable linker, and a DNA topoisomerase I inhibitor payload. Here we assessed SHR-A1811 in HER2-expressing\/mutated unresectable, advanced, or metastatic solid tumors.<br \/><b>Methods:<\/b> Pts were eligible if they had HER2 positive breast cancer (BC), HER2 positive gastric\/GEJ carcinoma, HER2 low-expressing BC, HER2-expressing\/mutated NSCLC, or other HER2-expressing\/mutated solid tumors, and were refractory or intolerant to standard therapy. SHR-A1811 at doses of 1.0-8.0 mg\/kg was given Q3W (IV). The primary endpoints were DLT, safety, and the RP2D.<br \/><b>Results: <\/b>From Sep 7, 2020 to Sep 28, 2022, 250 pts who had undergone a median of 3 prior treatment lines in the metastatic setting received at least one dose of SHR-A1811 in dose escalation, PK expansion, and indication expansion part. As of data cutoff on Sep 28, 2022, 1 pt experienced DLT. Treatment-related adverse events (TRAEs) were reported in 243 (97.2%) pts. Grade &#8805;3 TRAEs, serious TRAEs, and treatment-related deaths were reported in 131 (52.4%), 31 (12.4%), and 3 (1.2%) pts, respectively. Interstitial lung disease (AESI) was reported in 8 (3.2%) pts. Exposures of SHR-A1811, total antibody, and the payload were generally proportional to dose from 3.2 to 8.0 mg\/kg. ORR was 61.6% (154\/250, 95% CI 55.3-67.7) in all pts. Objective responses were observed in pts with HER2 positive BC (88\/108, ORR 81.5%, 95% CI 72.9-88.3), HER2-low BC (43\/77, ORR 55.8%, 95% CI 44.1-67.2), urothelial carcinoma (7\/11), colorectal cancer (3\/10), gastric\/GEJ carcinoma (5\/9), biliary tract cancer (5\/8), NSCLC (1\/3), endometrial cancer (1\/2), and H&#38;N cancer (1\/1). Subgroup analyses of ORR are shown in Table 1. The 6-month PFS rate was 73.9% in all pts.<br \/><b>Conclusions:<\/b> SHR-A1811 was well-tolerated and showed promising antitumor activity in heavily pretreated advanced solid tumors.<br \/><table border=\"1\"  cellpadding=\"1\" class=\"DisplayTable\" id=\"{B2A9602A-E622-49BB-8660-CEE4D85FD0AA}\"><caption>Table 1. Subgroup analyses of ORR<\/caption><tr><td rowspan=\"1\" colspan=\"4\">No. of prior treatment lines in metastatic setting in all pts (N=250)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\">HER2 positive BC (N=108)<\/td><td rowspan=\"1\" colspan=\"1\">HER2-low BC (N=77)<\/td><td rowspan=\"1\" colspan=\"1\">Other tumor types (N=65)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">&#8804;3<\/td><td rowspan=\"1\" colspan=\"1\">81.8% (45\/55)<\/td><td rowspan=\"1\" colspan=\"1\">58.7% (27\/46)<\/td><td rowspan=\"1\" colspan=\"1\">36.7% (18\/49)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">&gt;3<\/td><td rowspan=\"1\" colspan=\"1\">81.1% (43\/53)<\/td><td rowspan=\"1\" colspan=\"1\">51.6% (16\/31)<\/td><td rowspan=\"1\" colspan=\"1\">31.3% (5\/16)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"4\">Prior anti-HER2 therapies in pts with BC (N=185)*<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\">HER2 positive BC (N=108)<\/td><td rowspan=\"1\" colspan=\"1\">HER2-low BC (N=77)<\/td><td rowspan=\"1\" colspan=\"1\">All BC (N=185)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">Any<\/td><td rowspan=\"1\" colspan=\"1\">82.2% (88\/107, 73.7-89.0)<\/td><td rowspan=\"1\" colspan=\"1\">68.8% (11\/16, 41.3-89.0)<\/td><td rowspan=\"1\" colspan=\"1\">80.5% (99\/123, 72.4-87.1)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">Trastuzumab<\/td><td rowspan=\"1\" colspan=\"1\">81.9% (86\/105, 73.2-88.7)<\/td><td rowspan=\"1\" colspan=\"1\">75.0% (9\/12, 42.8-94.5)<\/td><td rowspan=\"1\" colspan=\"1\">81.2% (95\/117, 72.9-87.8)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">Pertuzumab<\/td><td rowspan=\"1\" colspan=\"1\">83.0% (39\/47, 69.2-92.4)<\/td><td rowspan=\"1\" colspan=\"1\">100% (5\/5, 47.8-100)<\/td><td rowspan=\"1\" colspan=\"1\">84.6% (44\/52, 71.9-93.1)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">Pyrotinib<\/td><td rowspan=\"1\" colspan=\"1\">86.9% (53\/61, 75.8-94.1)<\/td><td rowspan=\"1\" colspan=\"1\">71.4% (5\/7, 29.0-96.3)<\/td><td rowspan=\"1\" colspan=\"1\">85.3% (58\/68, 74.6-92.7)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">Lapatinib<\/td><td rowspan=\"1\" colspan=\"1\">80.0% (28\/35, 63.1-91.6)<\/td><td rowspan=\"1\" colspan=\"1\">100% (1\/1, 2.5-100)<\/td><td rowspan=\"1\" colspan=\"1\">80.6% (29\/36, 64.0-91.8)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">T-DM1<\/td><td rowspan=\"1\" colspan=\"1\">82.4% (14\/17, 56.6-96.2)<\/td><td rowspan=\"1\" colspan=\"1\">100% (3\/3, 29.2-100)<\/td><td rowspan=\"1\" colspan=\"1\">85.0% (17\/20, 62.1-96.8)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">Other HER2-ADC (except T-DM1)**<\/td><td rowspan=\"1\" colspan=\"1\">60.0% (9\/15, 32.3-83.7)<\/td><td rowspan=\"1\" colspan=\"1\">50.0% (2\/4, 6.8-93.2)<\/td><td rowspan=\"1\" colspan=\"1\">57.9% (11\/19, 33.5-79.8)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"4\">ORR in pts with tumor types other than BC (N=65)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\">HER2 IHC3+ or IHC2+\/ISH+ (N=36)<\/td><td rowspan=\"1\" colspan=\"1\">HER2 IHC2+\/ISH- or IHC1+ or unknown (N=29)<\/td><td rowspan=\"1\" colspan=\"1\">All other tumor types (N=65)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">% (n\/N)<\/td><td rowspan=\"1\" colspan=\"1\">38.9% (14\/36)<\/td><td rowspan=\"1\" colspan=\"1\">31.0% (9\/29)<\/td><td rowspan=\"1\" colspan=\"1\">35.4% (23\/65)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"4\">ORR was shown as % (n\/N, 95% CI) or % (n\/N). *ORR is calculated using the number of subjects previously treated with anti-HER2 cancer therapy in advanced\/metastatic setting as denominator; 2-sided 95% CIs are estimated using Clopper-Pearson method. **Includes RC48-ADC, A166, DP303c, MRG002, ARX788, TAA013, DX126-262, PF-06804103, and BAT8001.<\/td><\/tr><\/table>","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Antibody-drug conjugate (ADC),HER2,Solid tumors,Breast cancer,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Herui Yao<\/i><\/u><\/presenter>, <presenter><i>Min Yan<\/i><\/presenter>, <presenter><i>Zhongsheng Tong<\/i><\/presenter>, <presenter><i>Xinhong Wu<\/i><\/presenter>, <presenter><i>Min-Hee Ryu<\/i><\/presenter>, <presenter><i>Jee Hyun Kim<\/i><\/presenter>, <presenter><i>John Park<\/i><\/presenter>, <presenter><i>Yahua Zhong<\/i><\/presenter>, <presenter><i>Weiqing Han<\/i><\/presenter>, <presenter><i>Caigang Liu<\/i><\/presenter>, <presenter><i>Mark Voskoboynik<\/i><\/presenter>, <presenter><i>Qun Qin<\/i><\/presenter>, <presenter><i>Jian Zhang<\/i><\/presenter>, <presenter><i>Minal Barve<\/i><\/presenter>, <presenter><i>Ana Acuna-Villaorduna<\/i><\/presenter>, <presenter><i>Vinod Ganju<\/i><\/presenter>, <presenter><i>Seock-Ah Im<\/i><\/presenter>, <presenter><i>Changsheng Ye<\/i><\/presenter>, <presenter><i>Yongmei Yin<\/i><\/presenter>, <presenter><i>Amitesh C. Roy<\/i><\/presenter>, <presenter><i>Li-Yuan Bai<\/i><\/presenter>, <presenter><i>Yung-Chang Lin<\/i><\/presenter>, <presenter><i>Chia-Jui Yen<\/i><\/presenter>, <presenter><i>Hui Li<\/i><\/presenter>, <presenter><i>Ki Young Chung<\/i><\/presenter>, <presenter><i>Shanzhi Gu<\/i><\/presenter>, <presenter><i>Jun Qian<\/i><\/presenter>, <presenter><i>Yuee Teng<\/i><\/presenter>, <presenter><i>Yiding Chen<\/i><\/presenter>, <presenter><i>Yu Shen<\/i><\/presenter>, <presenter><i>Kaijing Zhao<\/i><\/presenter>, <presenter><i>Shangyi Rong<\/i><\/presenter>, <presenter><i>Xiaoyu Zhu<\/i><\/presenter>, <presenter><i>Erwei Song<\/i><\/presenter>. Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China, Hubei Cancer Hospital, Wuhan, China, Asan Medical Center, Seoul, Korea, Republic of, Seoul National University  Bundang Hospital, Seongnam, Korea, Republic of, Macquarie University Hospital in Macquarie Park, Sydney, Australia, Zhongnan Hospital of Wuhan University, Wuhan, China, Hunan Cancer Hospital, Changsha, China, Shengjing Hospital of China Medical University, Shenyang, China, Alfred Health, Melbourne, Australia, Xiangya Hospital Central South University, Changsha, China, Fudan University Shanghai Cancer Center, Shanghai, China, Mary Crowley Cancer Research, Dallas, TX, Montefiore-Einstein Center for Cancer Care, Bronx, NY, PASO Medical, Melbourne, Australia, Seoul National University, Seoul, Korea, Republic of, Nanfang Hospital Southern Medical University, Guangzhou, China, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, Southern Oncology Clinical Research Unit, Adelaide, Australia, China Medical University Hospital, Taichung, Taiwan, Chang Gung Memorial Hospital, Taoyuan, Taiwan, National Cheng Kung University Hospital, Tainan, Taiwan, Sichuan Cancer Hospital, Chengdu, China, Ghs Greenville Memorial Medical Center, Greenville, SC, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, The First Hospital of China Medical University, Shenyang, China, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China","CSlideId":"","ControlKey":"ab69e4f0-738e-4bbb-b6e5-333a8e83574e","ControlNumber":"9477","DisclosureBlock":"&nbsp;<b>H. Yao, <\/b> None..<br><b>M. Yan, <\/b> None..<br><b>Z. Tong, <\/b> None..<br><b>X. Wu, <\/b> None..<br><b>M. Ryu, <\/b> None..<br><b>J. H. Kim, <\/b> None..<br><b>J. Park, <\/b> None..<br><b>Y. Zhong, <\/b> None.&nbsp;<br><b>W. Han, <\/b> <br><b>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/b> Grant\/Contract.<br><b>C. Liu, <\/b> None..<br><b>M. Voskoboynik, <\/b> None..<br><b>Q. Qin, <\/b> None..<br><b>J. Zhang, <\/b> None..<br><b>M. Barve, <\/b> None..<br><b>A. Acuna-Villaorduna, <\/b> None..<br><b>V. Ganju, <\/b> None..<br><b>S. Im, <\/b> None..<br><b>C. Ye, <\/b> None..<br><b>Y. Yin, <\/b> None..<br><b>A. C. Roy, <\/b> None..<br><b>L. Bai, <\/b> None..<br><b>Y. Lin, <\/b> None..<br><b>C. Yen, <\/b> None..<br><b>H. Li, <\/b> None..<br><b>K. Y. Chung, <\/b> None.&nbsp;<br><b>S. Gu, <\/b> <br><b>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/b> Grant\/Contract. <br><b>J. Qian, <\/b> <br><b>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/b> Grant\/Contract.<br><b>Y. Teng, <\/b> None..<br><b>Y. Chen, <\/b> None.&nbsp;<br><b>Y. Shen, <\/b> <br><b>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/b> Employment. <br><b>K. Zhao, <\/b> <br><b>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/b> Employment. <br><b>S. Rong, <\/b> <br><b>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/b> Employment. <br><b>X. Zhu, <\/b> <br><b>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/b> Employment.<br><b>E. Song, <\/b> None.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10313","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"7","PosterboardNumber":"7","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT175","PresenterBiography":null,"PresenterDisplayName":"Herui Yao, MD","PresenterKey":"ff27645e-56a8-4d80-8393-2b8c4bd3c63d","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT175. <b>Safety, tolerability, pharmacokinetics, and antitumor activity of SHR-A1811 in HER2-expressing\/mutated advanced solid tumors: A global phase 1, multi-center, first-in-human study<\/b>","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"732","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"<b>Safety, tolerability, pharmacokinetics, and antitumor activity of SHR-A1811 in HER2-expressing\/mutated advanced solid tumors: A global phase 1, multi-center, first-in-human study<\/b>","Topics":null,"cSlideId":""},{"Abstract":"INTRODUCTION: Activated Tregs in the tumor micro-environment are correlated with poor outcomes, and are considered as key players in tumor immune-escape. So far, Treg depletion has not been successful in patients, either because adequate Treg depletion was not achieved or because Teff cells have either been impacted or depleted as well. RG6292 is the first anti-human CD25 antibody developed to specifically deplete human Tregs while preserving IL-2R STAT5 signaling and Teff activity. It has been optimized for ADCC and selective depletion of cells with high CD25 density (Treg).<br \/>MATERIALS and METHODS: Adult patients with advanced solid tumors were given RG6292 i.v. Q3W as monotherapy (S1: NCT04158583) or in combination with atezolizumab 1200 mg Q3W (S2: NCT04642365) in a Ph1 dose escalation study. 76 pts have been treated at dose levels ranging from 0.3 mg to 165 mg in S1 and 48 pts at dose levels ranging from 0.3 mg to 160 mg in S2. In both studies a Bayesian logistic regression model with overdose control guided dose escalation was utilized. Data cutoff was May 27, 2022. Pharmacokinetic and pharmacodynamic analyses were undertaken in peripheral blood and tumor tissue. PK\/PD modeling applied to Treg and Teff cells helped characterize and identify the optimal therapeutic window to ensure (1) relevant Treg depletion and (2) limited impact on T effector.<br \/>RESULTS: RG6292 has a linear and time independent PK with no ADA detected. A Population PK-PD modeling approach was applied to Treg and Teff cells in the periphery. To predict the RG6292 effects in the tumor microenvironment (TME), the PK\/PD relationships observed and characterized in the periphery for all cell subpopulations were considered the same, a tumor uptake factor of 15% was considered. At steady-state trough, a 70 mg Q3W dose was predicted to lead to 72% of patients with concentration above the Treg (%CD4) EC50 in tumor and 40% of patients with concentration above the Non-Treg (%CD4) EC50 in plasma. RG6292 induced a dose-dependent peripheral and intratumoral Treg depletion in on-treatment biopsies taken 28 days after initiation of treatment. Treatment did not appear to impact the number nor the functionality of intratumoral CD8 T cells nor any evident effect observed on PDL1 expression. In blood, stable levels of all other immune cells were observed after treatment. Moreover, in both studies a marginal increase of IFNg, CXCL10, IL-10, TNF was observed. No consistent gene expression alterations nor immune signatures could be observed when comparing BSL vs OT biopsies in S1.<br \/>CONCLUSION: RG6292, consistent with its proposed mechanism of action, induces profound and preferential depletion of Treg cells over CD8+CD25+ in the periphery and in the TME at clinically safe doses between 35-70mg. Further development of RG6292 is currently being explored.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Regulatory T cells,Phase I,Pharmacodynamics,Pharmacokinetics,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Tamara Tanos<\/i><\/u><\/presenter>, <presenter><i>Kevin Smart<\/i><\/presenter>, <presenter><i>Valentina Gambardella<\/i><\/presenter>, <presenter><i>Kristoffer Rohrberg Kristoffer Rohrberg<\/i><\/presenter>, <presenter><i>Michael Ong<\/i><\/presenter>, <presenter><i>Maria Esperanza Rodriguez Ruiz<\/i><\/presenter>, <presenter><i>Jean-Pascal Machiels<\/i><\/presenter>, <presenter><i>Miguel Fernndez Sanmamed<\/i><\/presenter>, <presenter><i>Josep Tabernero<\/i><\/presenter>, <presenter><i>Anna Spreafico<\/i><\/presenter>, <presenter><i>Daniel Renouf<\/i><\/presenter>, <presenter><i>Stephen Luen<\/i><\/presenter>, <presenter><i>Rachel Galot<\/i><\/presenter>, <presenter><i>Bernard Doger<\/i><\/presenter>, <presenter><i>Emiliano Calvo<\/i><\/presenter>, <presenter><i>Aung Naing<\/i><\/presenter>, <presenter><i>Samira Curdt<\/i><\/presenter>, <presenter><i>Nicolas Staedler<\/i><\/presenter>, <presenter><i>Mike Flores<\/i><\/presenter>, <presenter><i>Enrique Gmez Alcaide<\/i><\/presenter>, <presenter><i>Chiahuey Ooi<\/i><\/presenter>, <presenter><i>Michael Hettich<\/i><\/presenter>, <presenter><i>Sebastian Dziadek<\/i><\/presenter>, <presenter><i>Yuying Xie<\/i><\/presenter>, <presenter><i>Gabriel Schnetzler<\/i><\/presenter>, <presenter><i>Theresa Kolben<\/i><\/presenter>, <presenter><i>Linxinyu Xu<\/i><\/presenter>, <presenter><i>Vaios Karanikas<\/i><\/presenter>, <presenter><i>Christophe Boetsch<\/i><\/presenter>. Roche Innovation Centre Basel, Basel, Switzerland, Roche Innovation Centre Welwyn, Welwyn, United Kingdom, INCLIVA-Biomedical Research Institute, HCUV, Valencia, Spain, Department of Oncology, Copenhagen University Hospital  Rigshospitalet, Copenhagen, Denmark, The Ottawa Hospital, Ottawa, ON, Canada, Universidad de Navarra, Navarra, Spain, Institut Roi Albert II cancer center, Brussels, Belgium, Department of Medical Oncology, Clinica Universidad de Navarra,, Pamplona, Spain, Vall dHebron Institute of Oncology, Barcelona, Spain, Princess Margaret Cancer Centre, Toronto, ON, Canada, British Columbia Cancer Agency, Vancouver Centre, Vancouver, BC, Canada, Peter MacCallum Cancer Centre, Melbourne, Australia, Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc and Institut de Recherche Clinique et Exprimentale, Universit Catholique de Louvain, Brussels, Belgium, START Madrid-FJD, Hospital Fundacin Jimnez Daz, Madrid, Spain, START Madrid-CIOCC, Centro Integral Oncolgico Clara Campal, Madrid, Spain, MD Anderson Cancer Center, Houston, TX, Roche Innovation Centre Munich, Munich, Germany, Roche Molecular Systems, Inc., Tuscon, AZ, Canada Pharma Campus, Mississauga, ON, Canada, Roche Innovation Centre Zurich, Zurich, Switzerland","CSlideId":"","ControlKey":"3bade694-bae1-40b8-9d23-427bf15937b2","ControlNumber":"9482","DisclosureBlock":"<b>&nbsp;T. Tanos, <\/b> <br><b>F. Hoffmann- La Roche Ltd<\/b> Employment. <br><b>K. Smart, <\/b> <br><b>F. Hoffmann- La Roche Ltd<\/b> Employment.<br><b>V. Gambardella, <\/b> None.&nbsp;<br><b>K. Kristoffer Rohrberg, <\/b> <br><b>Lilly<\/b> Other, Coordinating PI, Financial interest, Institutional, Compensation for conduction of clinical trial. <br><b>Roche\/Genentech<\/b> Other, Coordinating PI, Financial interest, Institutional, Compensation for conduction of clinical trial. <br><b>Bristol-Myers Squibb<\/b> Other, Coordinating PI, Financial interest, Institutional, Compensation for conduction of clinical trial. <br><b>Symphogen<\/b> Other, Coordinating PI, Financial interest, Institutional, Compensation for conduction of clinical trial. <br><b>Pfizer<\/b> Other, Coordinating PI, Financial interest, Institutional, Compensation for conduction of clinical trial. <br><b>Novartis<\/b> Other, Coordinating PI, Financial interest, Institutional, Compensation for conduction of clinical trial. <br><b>Bayer<\/b> Other, Coordinating PI, Financial interest, Institutional, Compensation for conduction of clinical trial. <br><b>Alligator Bioscience<\/b> Other, Coordinating PI, Financial interest, Institutional, Compensation for conduction of clinical trial. <br><b>Incyte<\/b> Other, Other, Financial interest, Institutional, Compensation for conduction of clinical trial.. <br><b>Genmab<\/b> Other, Coordinating PI, Financial interest, Institutional, Compensation for conduction of clinical trial. <br><b>Puma Biotechnology<\/b> Other, Other, Financial interest, Institutional, Compensation for conduction of clinical trial.. <br><b>Orion Clinical<\/b> Other, Other, Financial interest, Institutional, Compensation for conduction of clinical trial.. <br><b>Bioinvent<\/b> Other, Coordinating PI, Financial interest, Institutional, Compensation for conduction of clinical trial.. <br><b>Monta Bioscience<\/b> Other, Coordinating PI, Financial interest, Institutional, Compensation for conduction of clinical trial.<br><b>M. Ong, <\/b> None..<br><b>M. Ruiz, <\/b> None.&nbsp;<br><b>J. Machiels, <\/b> <br><b>Pfizer<\/b> Grant\/Contract, Travel, Other, Advisory board member or speaker with honoraria (managed by my Institution). <br><b>Roche<\/b> Grant\/Contract, Other, Advisory board member or speaker with honoraria (managed by my Institution). <br><b>Astra\/Zeneca<\/b> Grant\/Contract, Other, Advisory board member or speaker with honoraria (managed by my Institution). <br><b>Bayer<\/b> Grant\/Contract, Other, Advisory board member or speaker with honoraria (managed by my Institution). <br><b>Innate<\/b> Grant\/Contract, Other, Advisory board member or speaker with honoraria (managed by my Institution). <br><b>Merck Serono<\/b> Grant\/Contract, Travel, Other, Advisory board member or speaker with honoraria (managed by my Institution). <br><b>Boerhinger<\/b> Grant\/Contract, Other, Advisory board member or speaker with honoraria (managed by my Institution). <br><b>BMS<\/b> Grant\/Contract, Travel, Other, Advisory board member or speaker with honoraria (managed by my Institution). <br><b>Novartis<\/b> Grant\/Contract, Other, Advisory board member or speaker with honoraria (managed by my Institution). <br><b>Janssen<\/b> Grant\/Contract, Other, Advisory board member or speaker with honoraria (managed by my Institution). <br><b>Incyte<\/b> Grant\/Contract, Other, Advisory board member or speaker with honoraria (managed by my Institution). <br><b>Cue Biopharma<\/b> Grant\/Contract, Other, Advisory board member or speaker with honoraria (managed by my Institution). <br><b>ALX Oncology<\/b> Grant\/Contract, Other, Advisory board member or speaker with honoraria (managed by my Institution). <br><b>iTEOS<\/b> Grant\/Contract, Other, Advisory board member or speaker with honoraria (managed by my Institution). <br><b>eTheRNA<\/b> Grant\/Contract, Other, Advisory board member or speaker with honoraria (managed by my Institution). <br><b>NEKTAR<\/b> Grant\/Contract, Other, Advisory board member or speaker with honoraria (managed by my Institution). <br><b>F-Star<\/b> Grant\/Contract, Other, Advisory board member or speaker with honoraria (managed by my Institution). <br><b>Seagen<\/b> Grant\/Contract, Other, Advisory board member or speaker with honoraria (managed by my Institution). <br><b>Genmab<\/b> Grant\/Contract, Other, Advisory board member or speaker with honoraria (managed by my Institution). <br><b>Astellas<\/b> Grant\/Contract, Other, Advisory board member or speaker with honoraria (managed by my Institution). <br><b>M. Sanmamed, <\/b> <br><b>Roche<\/b> Grant\/Contract, Other, personal fees. <br><b>BMS<\/b> Grant\/Contract, personal fees.<br><b>J. Tabernero, <\/b> None..<br><b>A. Spreafico, <\/b> None..<br><b>D. Renouf, <\/b> None..<br><b>S. Luen, <\/b> None..<br><b>R. Galot, <\/b> None..<br><b>B. Doger, <\/b> None.&nbsp;<br><b>E. Calvo, <\/b> <br><b>START<\/b> Employment, Stock, Other Securities. <br><b>Oncoart Associated<\/b> Stock, Other Securities. <br><b>Nanobiotix<\/b> Other, Consulting or Advisory Role. <br><b>Janssen-Cilag<\/b> Other, Consulting or Advisory Role. <br><b>Roche\/Genentech<\/b> Other, Consulting or Advisory Role. <br><b>TargImmune Therapeutics<\/b> Other, Consulting or Advisory Role. <br><b>Servier<\/b> Other, Consulting or Advisory Role. <br><b>Bristol-Myers Squibb<\/b> Other, Consulting or Advisory Role. <br><b>Amunix<\/b> Other, Consulting or Advisory Role. <br><b>Adcendo<\/b> Other, Consulting or Advisory Role. <br><b>Anaveon<\/b> Other, Consulting or Advisory Role. <br><b>AstraZeneca\/MedImmune<\/b> Other, Consulting or Advisory Role. <br><b>Chugai Pharma<\/b> Other, Consulting or Advisory Role. <br><b>MonTa<\/b> Other, Consulting or Advisory Role. <br><b>MSD Oncology<\/b> Other, Consulting or Advisory Role. <br><b>Nouscom<\/b> Other, Consulting or Advisory Role. <br><b>Novartis<\/b> Other, Consulting or Advisory Role. <br><b>OncoDNA<\/b> Other, Consulting or Advisory Role. <br><b>T-Knife<\/b> Other, Consulting or Advisory Role. <br><b>Elevation Oncology<\/b> Other, Consulting or Advisory Role. <br><b>A. Naing, <\/b> <br><b>EMD Serono,<\/b> Grant\/Contract. <br><b>MedImmune<\/b> Grant\/Contract. <br><b>Healios Onc.<\/b> Grant\/Contract. <br><b>Nutrition,<\/b> Grant\/Contract. <br><b>Atterocor\/Millendo<\/b> Grant\/Contract. <br><b>Amplimmune<\/b> Grant\/Contract. <br><b>ARMO BioSciences,<\/b> Grant\/Contract. <br><b>Karyopharm Therapeutics,<\/b> Grant\/Contract. <br><b>Incyte,<\/b> Grant\/Contract. <br><b>Novartis<\/b> Grant\/Contract. <br><b>Regeneron<\/b> Grant\/Contract. <br><b>Merck<\/b> Grant\/Contract, Other, advisory board\/Consulting fees. <br><b>Bristol-Myers Squibb,<\/b> Grant\/Contract, Other, advisory board\/Consulting fees. <br><b>Pfizer<\/b> Grant\/Contract. <br><b>CytomX Therapeutics,<\/b> Grant\/Contract, Other, advisory board\/Consulting fees. <br><b>Neon Therapeutics,<\/b> Grant\/Contract. <br><b>Calithera Biosciences,<\/b> Grant\/Contract. <br><b>TopAlliance Biosciences,<\/b> Grant\/Contract. <br><b>Eli Lilly<\/b> Grant\/Contract. <br><b>Kymab<\/b> Grant\/Contract. <br><b>S. Curdt, <\/b> <br><b>F. Hoffmann- La Roche Ltd<\/b> Employment. <br><b>N. Staedler, <\/b> <br><b>F. Hoffmann-La Roche Ltd.<\/b> Employment. <br><b>M. Flores, <\/b> <br><b>F. Hoffmann- La Roche Ltd<\/b> Employment. <br><b>E. Alcaide, <\/b> <br><b>F. Hoffmann- La Roche Ltd<\/b> Employment. <br><b>C. Ooi, <\/b> <br><b>F. Hoffmann- La Roche Ltd<\/b> Employment, Stock. <br><b>M. Hettich, <\/b> <br><b>F. Hoffmann- La Roche Ltd<\/b> Employment. <br><b>S. Dziadek, <\/b> <br><b>F. Hoffmann- La Roche Ltd<\/b> Employment, Stock. <br><b>Y. Xie, <\/b> <br><b>F. Hoffmann- La Roche Ltd<\/b> Employment. <br><b>G. Schnetzler, <\/b> <br><b>F. Hoffmann- La Roche Ltd<\/b> Employment. <br><b>T. Kolben, <\/b> <br><b>F. Hoffmann- La Roche Ltd<\/b> Employment, Stock. <br><b>L. Xu, <\/b> <br><b>F. Hoffmann- La Roche Ltd<\/b> Employment. <br><b>V. Karanikas, <\/b> <br><b>F. Hoffmann- La Roche Ltd<\/b> Employment, Stock, Stock Option, Patent. <br><b>C. Boetsch, <\/b> <br><b>F. Hoffmann-La Roche Ltd.<\/b> Employment.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10314","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"8","PosterboardNumber":"8","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT176","PresenterBiography":null,"PresenterDisplayName":"Tamara Tanos, PhD","PresenterKey":"d0910f11-a9b7-4059-82e9-663ea5f568e5","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT176. Pharmacokinetic\/pharmacodynamic (PK\/PD) relationships of the novel Treg depleter RG6292 in Phase Ia and Ib studies in patients with solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"732","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Pharmacokinetic\/pharmacodynamic (PK\/PD) relationships of the novel Treg depleter RG6292 in Phase Ia and Ib studies in patients with solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Background: CBA-1205 is a novel humanized anti-delta-like 1 homolog (DLK-1) antibody. It is a glycoengineered antibody by GlymaxX&#174; technology to potentiate antibody-dependent cellular cytotoxicity activity. DLK-1 is a membrane protein with 6 tandem EGF-like motifs in extracellular region. Overexpression of DLK-1 has been reported in variety of cancer types including hepatocellular carcinoma (HCC), suggesting that DLK-1 could be an ideal target for cancer therapy.<br \/>Methods: This is a first in human, multicenter, open-label Phase I study. The purpose of part 1 is to evaluate the safety and tolerability in patients with advanced solid tumors who had no standard therapy or were refractory or intolerant to standard therapies and to determine the starting dose for part 2 in HCC patients. The standard 3+3 dose escalation design was utilized in seven cohorts (0.1, 0.3, 1, 3, 10, 20, 30 mg\/kg). CBA-1205 was administered at 2-week intervals in a 28-day cycle. If the patient had no Dose Limiting Toxicity (DLT) during 28 days after the first two doses, CBA-1205 administration will be continued for further cycles unless any of the criteria for discontinuation. Serum DLK-1 concentration before the start of CBA-1205 administration was analyzed using the Human Pref-1\/DLK1\/FA1 DuoSet ELISA (R&#38;D Systems, Inc.). Immunohistochemical analysis of DLK-1 expression in the archival tumor specimen was determined in FFPE tissue sections using mouse anti-hDLK-1 antibody (clone DI-2-20, Chiome Bioscience).<br \/>Results: 22 patients with advanced solid tumors were enrolled. CBA-1205 was well tolerated in these patients and no DLT was observed even at the highest dose tested. No &#8805; Grade 3 treatment related adverse events was observed throughout the study periods. The serum concentration of CBA-1205 increased dose-proportionally. The exposure to CBA-1205 exceeded the effective concentrations observed in a mouse xenograft model. No serum anti-CBA-1205 antibody was detected. The disease control was seen in 8 patients (38.1%, all with SD). Especially, long SD was observed in 3 patients with invasive thymoma, malignant melanoma, and pancreatic carcinoma, where progression free survival (PFS) was 39, 72(ongoing, at data cutoff), and 41 weeks, respectively. The serum concentration of soluble DLK-1 was detected in 6 out of 22 patients. Patients with SD by the best overall response had a higher rate of detectable serum DLK-1 concentration and a higher mean concentration than patients with PD. No DLK-1 expression in tumor was detected by IHC method, in 14 patients who consented to use the archival tumor specimens.<br \/>Conclusions: CBA-1205 was well tolerated without any severe toxicity in patients with advanced solid tumors.Part 2 of this Phase I study with two cohorts (20, 30 mg\/kg) in patients with unresectable advanced\/recurrent HCC refractory or intolerable to the standard therapy has been initiated.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Antibody-dependent cellular cytotoxicity (ADCC),delta-like 1 homolog (DLK-1),First in class,First in human (FIH),"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Masafumi Ikeda<\/i><\/u><\/presenter>, <presenter><i>Nobuaki Matsubara<\/i><\/presenter>, <presenter><i>Chihiro Kondoh<\/i><\/presenter>, <presenter><i>Shose Taoka<\/i><\/presenter>, <presenter><i>Yuki Katsuya<\/i><\/presenter>, <presenter><i>Takafumi Koyama<\/i><\/presenter>, <presenter><i>Noboru Yamamoto<\/i><\/presenter>. National Cancer Center Hospital East, Chiba, Japan, Chiome Bioscience, Tokyo, Japan, National Cancer Center Hospital, Tokyo, Japan","CSlideId":"","ControlKey":"e44b6f89-fd9b-478b-9a92-30009cb3f94f","ControlNumber":"9522","DisclosureBlock":"<b>&nbsp;M. Ikeda, <\/b> <br><b>AstraZeneca; Bayer; Bristol-Myers Squibb; Chiome Bioscience; Chugai; Delta-Fly Phama; Eisai; Eli Lilly Japan; J-Pharma; Merck biopharma; Merus.N.V.; MSD; NIHON SERVIER; Novartis; Ono; Pfizer<\/b> Grant\/Contract. <br><b>Syneos Health; Invitae<\/b> Grant\/Contract. <br><b>N. Matsubara, <\/b> <br><b>Janssen; AstraZeneca; Bayer; Roche; MSD; Taiho; Astellas; Amgen; Eisai; Eli Lilly; PRA Health Science; Takeda; Pfizer; Seagen; Chugai<\/b> Grant\/Contract. <br><b>C. Kondoh, <\/b> <br><b>Astellas Pharma<\/b> Other, Clinial trial, Lecture fee. <br><b>AstraZeneca; Eisai; Bristol-Myers Squibb; Ono Pharmaceutical; Chugai Pharmaceutical; Takeda Pharmaceutical; Merck; Merck KGaA<\/b> Other, Lecture fee. <br><b>S. taoka, <\/b> <br><b>Chiome Bioscience<\/b> Fiduciary Officer, Stock, Stock Option.<br><b>Y. Katsuya, <\/b> None.&nbsp;<br><b>T. Koyama, <\/b> <br><b>PACT Pharma; Chugai; Daiichi-Sankyo; Novartis; Lilly; Sysmex; Amgen; AstraZeneca; Pfizer; Takeda<\/b> Grant\/Contract. <br><b>N. Yamamoto, <\/b> <br><b>Astellas; Chugai; Eisai; Taiho; BMS; Pfizer; Novartis; Eli Lilly; AbbVie; Daiichi-Sankyo; Bayer; Boehringer Ingelheim; Kyowa Kirin; Takeda; ONO; Janssen Pharma; MSD; MERCK; GSK; Sumitomo Pharma<\/b> Grant\/Contract. <br><b>Chiome Bioscience; Otsuka; Carna Biosciences; Genmab; Shionogi; TORAY; KAKEN; AstraZeneca; Cimic<\/b> Grant\/Contract.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10315","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"9","PosterboardNumber":"9","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT177","PresenterBiography":null,"PresenterDisplayName":"Masafumi Ikeda, MD","PresenterKey":"26fe5932-e320-43e2-87c8-8c1b8600c4d5","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT177. A phase I, first in human study of CBA-1205, glycoengineered humanized anti-DLK-1 monoclonal antibody in patients with advanced solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"732","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A phase I, first in human study of CBA-1205, glycoengineered humanized anti-DLK-1 monoclonal antibody in patients with advanced solid tumors","Topics":null,"cSlideId":""},{"Abstract":"<b>Background<\/b>: GQ1001 is a novel HER2-targeted antibody-drug conjugate (ADC) that was developed using innovative conjugation technologies coined intelligent Ligase-Dependent Conjugation (iLDC), that can significantly improves homogeneity and biostability of ADC. In preclinical studies, GQ1001 showed a robust anti-tumor response<i> <\/i>in<i> <\/i>multiple HER2+ models alone or in combination with HER2 TKIs and chemotherapeutics, and excellent pharmacokinetics and safety profiles in rats and monkeys due to low level of payload release. Herein we report the initial results of the ongoing phase Ia study, which aims to investigate the safety, tolerability, pharmacokinetics and antitumor activity of GQ1001 in subjects with HER2+ advanced solid tumors.<br \/><b>Methods<\/b>: In phase Ia dose escalation, a modified 3+3 model was adopted to assess the safety, dose-limiting toxicity (DLT) and maximal tolerable dose (MTD) or dose recommended for dose expansion (DRDE) of GQ1001. GQ1001 was administered intravenously as a monotherapy on Day 1 of 21-day cycles. The starting dose was 1.2 mg\/kg, followed by 2.4, 3.6, 4.8, 6.0, 7.2 and 8.4 mg\/kg.<br \/><b><\/b> <b>Results<\/b>: As of Dec. 28<sup>th<\/sup>, 2022, 32 subjects with HER2-positive advanced solid tumors, predominantly in breast (9), gastric or gastro-esophageal junction (9) and salivary gland (4), were enrolled and received GQ1001 treatment. Patients had a median 3 (range, 0-11) prior lines of therapies, and 37.5% of those previously received &#8805;2 lines of anti-HER2 therapies. Median exposure time of GQ1001 was 18.5 weeks. The longest treatment duration exceeded 370 days. No DLT was observed in all doses, MTD was not reached up to 8.4 mg\/kg, the highest dose tested. Treatment-related adverse events (TRAEs) occurred in 24 subjects (75%). The most common TRAEs (&#62;10.0%) were aspartate aminotransferase (AST) increased (37.5%), thrombocytopenia (28.1%), alanine aminotransferase (ALT) increased (25.0%), pyrexia (21.9%), anemia (18.8%), alkaline phosphatase increased (12.5%), vomiting (12.5%) and nausea (12.5%). Grade &#8805;3 TRAEs occurred in 9 subjects (28.1%), including 5 myelosuppression, 2 abnormal liver function, 1 hypertension and 1 vomiting. There were no drug-related deaths. The pharmacokinetics analysis showed the concentration of GQ1001 and TAb generally peaked rapidly and declined in a roughly biphasic manner. Among 15 evaluable subjects who received &#8805; 7.2 mg\/kg, 6 cases achieved confirmed partial response, and 3 had stable disease, the median progression-free survival was 4.8 months<br \/><b> <\/b> <b>Conclusions:<\/b> GQ1001 demonstrates an excellent tolerability and promising antitumor activity in heavily pretreated HER2-positive advanced solid tumors, supporting further evaluation of the safety and efficacy of GQ1001 at DRDE of 8.4 mg\/kg in the following phase Ib trial. (NCT04450732; sponsored by GeneQuantum Healthcare (Suzhou) Co., Ltd.)","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Antibody-drug conjugate (ADC),HER2,Solid tumors,First in human,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Charlotte Lemech<\/i><\/u><\/presenter>, <presenter><i>Chenfei Zhou<\/i><\/presenter>, <presenter><i>Xianbao Zhan<\/i><\/presenter>, <presenter><i>Yan Shi<\/i><\/presenter>, <presenter><i>Jieqiong Liu<\/i><\/presenter>, <presenter><i>Sarina A Piha-Paul<\/i><\/presenter>, <presenter><i>Gary Richardson<\/i><\/presenter>, <presenter><i>Gang Qin<\/i><\/presenter>, <presenter><i>Paul H. Song<\/i><\/presenter>, <presenter><i>Lili Shi<\/i><\/presenter>, <presenter><i>Yajun Sun<\/i><\/presenter>, <presenter><i>Yi Xia<\/i><\/presenter>. Scientia Clinical Research, Randwick, Australia, Ruijin Hospital, Shanghai, China, Changhai Hospital, Shanghai, China, Sun Yat Sen Hospital, Guangzhou, China, MD Anderson, Texas, TX, Cabrini Research, Malvern, Australia, GeneQuantum Healthcare (Suzhou) Co., Ltd., Suzhou, China, GeneQuantum Healthcare (Suzhou) Co., Ltd., Carmel, IN","CSlideId":"","ControlKey":"b20e7566-9a41-4d2e-9cf6-94a9ef332cd2","ControlNumber":"9523","DisclosureBlock":"&nbsp;<b>C. Lemech, <\/b> None..<br><b>C. Zhou, <\/b> None..<br><b>X. Zhan, <\/b> None.&nbsp;<br><b>Y. Shi, <\/b> <br><b>GeneQuantum Healthcare (Suzhou) Co., Ltd.<\/b> Employment.<br><b>J. Liu, <\/b> None..<br><b>S. Piha-Paul, <\/b> None..<br><b>G. Richardson, <\/b> None.&nbsp;<br><b>G. Qin, <\/b> <br><b>GeneQuantum Healthcare (Suzhou) Co., Ltd.<\/b> Employment. <br><b>P. H. Song, <\/b> <br><b>GeneQuantum Healthcare (Suzhou) Co., Ltd.<\/b> Employment. <br><b>L. Shi, <\/b> <br><b>GeneQuantum Healthcare (Suzhou) Co., Ltd.<\/b> Employment. <br><b>Y. Sun, <\/b> <br><b>GeneQuantum Healthcare (Suzhou) Co., Ltd.<\/b> Employment. <br><b>Y. Xia, <\/b> <br><b>GeneQuantum Healthcare (Suzhou) Co., Ltd.<\/b> Employment.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10316","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"10","PosterboardNumber":"10","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT178","PresenterBiography":null,"PresenterDisplayName":"Charlotte Lemech, MBBS","PresenterKey":"722c5516-90f4-4ab6-8476-ce725b501ee1","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT178. GQ1001: A next generation HER2-targeting ADC that exhibits promising early clinical efficacy with excellent tolerance in a multi-center, Phase Ia study","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"732","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"GQ1001: A next generation HER2-targeting ADC that exhibits promising early clinical efficacy with excellent tolerance in a multi-center, Phase Ia study","Topics":null,"cSlideId":""},{"Abstract":"<b>Background: <\/b>ICT01, an anti-BTN3A mAb, selectively activates &#947;9&#948;2 T cells resulting in remodeling of the tumor microenvironment by activated &#947;9&#948;2 T, CD8 T, and NK cells (EVICTION- NCT04243499; AACR 2022 CT188). Response to ICT01 depends on the baseline number of &#947;9&#948;2 T cells with many cancer patients having inadequate numbers due to prior chemotherapy and\/or the underlying malignancy. ICT01 plus IL-2 induces selective expansion of &#947;9&#948;2 T cells with minimal Treg expansion in NHPs and is currently being tested in the EVICTION-2 Trial, a phase I\/IIa, open-label study to characterize the safety, tolerability, pharmacodynamics, and antitumor activity of ICT01 in combination with low dose subcutaneous (LDSC) IL-2 in patients with advanced-stage solid tumors (NCT04243499).<b><\/b><br \/><b>Methods: <\/b>ICT01 (1, 5, 20 or 75 mg, IV Q3W) is given in combination with LDSC IL-2 (Proleukin&#174;, 1 or 2 MIU\/m<sup>2<\/sup>) on days 1-5 of the first 3 cycles and will be continued alone thereafter. Per dose combination two patients are enrolled for dose escalation based on the BOIN simulations to identify a safe and pharmacodynamically active dose combination(s) for Phase IIa expansion.<br \/><b><\/b> <b>Results: <\/b>To date, 9 patients with colorectal (n=6), ovarian (n=2) or pancreatic cancer (n=1) with a mean\/median of 6 prior lines of therapy have received at least their first cycle of ICT01 1, 5, 20 or 75 mg + IL-2 1MIU\/m<sup>2<\/sup> or ICT01 1mg + IL-2 2MIU\/m<sup>2<\/sup>. Treatment-related adverse events (TRAE) were mainly infusion related reactions comprising fever and chills grade 1 and 2 in 8\/9 patients, not different in severity from ICT01 or IL-2 monotherapy. No dose limiting toxicities were reported. By RECIST, Stable Disease was observed in 2\/6 patients with a Week 8 assessment. In all patients, a 2-to-9-fold increase in &#947;9&#948;2 T cells was observed for each of the 3 combination cycles, which is accompanied by peripheral activation, mobilization, and proliferation of CD8 T cells, NKs and granulocytes, which is consistent with the expected contribution of IL-2. Increased IFN&#947; and IL-8 levels (2.4-to-140 fold and 2-to-94 fold respectively) were observed within 24h after each dose of ICT01\/IL-2. Flow cytometry of Tregs in frozen PBMCs and IHC of tumor biopsies collected at baseline and on Day 28 are being analyzed to quantify tumor infiltration.<br \/><b>Conclusions<\/b> ICT01 plus LDSC IL-2 safely induced robust &#947;9&#948;2 T cell expansion leading to a broad immune response involving CD8 T cells, NKs, and granulocytes at lower doses than observed with ICT01 monotherapy. More patient data are needed to confirm that IL-2 potentiates the antitumor effects of ICT01 and that this leads to better clinical outcomes.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Immunotherapy,Monoclonal antibodies,Interleukin-2,Gamma-delta lymphocytes,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><i>Johann De Bono<\/i><\/presenter>, <presenter><i>Stphane Champiat<\/i><\/presenter>, <presenter><i>Francois-Xavier Danlos<\/i><\/presenter>, <presenter><i>Martin Wermke<\/i><\/presenter>, <presenter><i>Volker Kunzmann<\/i><\/presenter>, <presenter><i>Aude De Gassart<\/i><\/presenter>, <presenter><i>Emmanuel Valentin<\/i><\/presenter>, <presenter><i>Marina Iche<\/i><\/presenter>, <presenter><i>Maelle Mairesse<\/i><\/presenter>, <presenter><i>Patrick Brune<\/i><\/presenter>, <presenter><u><i>Katrien Lemmens<\/i><\/u><\/presenter>, <presenter><i>Aurlien Marabelle<\/i><\/presenter>, <presenter><i>Daniel Olive<\/i><\/presenter>, <presenter><i>Paul Frohna<\/i><\/presenter>. The Institute for Cancer Research and Royal Marsden, London, United Kingdom, Gustave Roussy, Paris, France, NCT\/UCC Early Clinical Trial Unit, Medical Faculty Carl Gustav Carus, Technical University,, Dresden, Germany, University Clinic of Wrzburg, Wrzburg, Germany, Imcheck Therapeutics, Marseille, France, Ilife Consulting, Paris, France, Centre de recherche en Cancrologie de Marseille, INSERM U1068, CNRS U7258, Aix Marseille Universit, Institut Paoli-Calmettes, Marseille, France","CSlideId":"","ControlKey":"aa76559e-ddbb-4b3b-ac5d-5e9bdfb4cbd9","ControlNumber":"9531","DisclosureBlock":"&nbsp;<b>J. de Bono, <\/b> None.&nbsp;<br><b>S. Champiat, <\/b> <br><b>Amgen<\/b> Travel, Other, Advisory Board, Principal Investigator of clinical trial. <br><b>Astrazeneca<\/b> Grant\/Contract, Travel, Other, Advisory Board, Honoraria. <br><b>Bristol Myers Squibb<\/b> Grant\/Contract, Travel, Other, Honoraria. <br><b>Merck<\/b> Grant\/Contract, Travel, Other, Honoraria, Principal Investigator of clinical trial. <br><b>Roche<\/b> Grant\/Contract, Travel, Other, Honoraria. <br><b>Ose Pharma<\/b> Travel. <br><b>Novartis<\/b> Other, Honoraria. <br><b>Sanofi<\/b> Grant\/Contract, Principal Investigator of clinical trial. <br><b>Janssen<\/b> Grant\/Contract, Honoraria. <br><b>Pfizer<\/b> Grant\/Contract.<br><b>F. Danlos, <\/b> None..<br><b>M. Wermke, <\/b> None..<br><b>V. Kunzmann, <\/b> None..<br><b>A. De Gassart, <\/b> None..<br><b>E. Valentin, <\/b> None..<br><b>M. Iche, <\/b> None..<br><b>M. Mairesse, <\/b> None..<br><b>P. Brune, <\/b> None..<br><b>K. Lemmens, <\/b> None.&nbsp;<br><b>A. Marabelle, <\/b> <br><b>Astrazeneca<\/b> Travel, Other, Advisory Board, Honoraria. <br><b>BMS<\/b> Grant\/Contract, Other, Advisory Board. <br><b>MSD<\/b> Grant\/Contract, Travel, Other, Advisory Board. <br><b>Servier<\/b> Other, Advisory Board. <br><b>Roche<\/b> Other, Advisory Board. <br><b>Boerignher Ingelheim<\/b> Grant\/Contract. <br><b>D. Olive, <\/b> <br><b>GlaxoSmithKline<\/b> Stock.<br><b>P. Frohna, <\/b> None.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10317","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"11","PosterboardNumber":"11","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT179","PresenterBiography":null,"PresenterDisplayName":"Katrien Lemmens, MD,PhD","PresenterKey":"100e37fd-179f-4278-b22e-6b2a824e906a","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT179. First-in-human study of ICT01, an anti-BTN3A activating monoclonal antibody in combination with low dose IL-2 in patients with advanced solid tumors (EVICTION-2 study)","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"732","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"First-in-human study of ICT01, an anti-BTN3A activating monoclonal antibody in combination with low dose IL-2 in patients with advanced solid tumors (EVICTION-2 study)","Topics":null,"cSlideId":""},{"Abstract":"<b>Background. <\/b>PRTX007 is an orally administered prodrug of PRX034, a toll-like receptor 7 (TLR7) agonist that elicits an unprecedented pattern of systemic immune induction in non-human primates and in humans. Notably, there is no evidence of NF-K&#946;-mediated systemic inflammation at drug levels that stimulate IFN-responsive pathways and corresponding downstream cellular processes, including activation of CD8<sup>+<\/sup> T cells and NK cells. We have previously reported interim results from a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study of PRTX007. PRTX007 demonstrated a favorable safety profile with no serious adverse events (SAEs) and a lack of the adverse events (AEs) historically associated with TLR7 agonists. Robust systemic immune induction was achieved, without counter-regulation or evidence of systemic inflammation, in participants receiving PRTX007 in the 300 - 500 mg MAD cohorts. This report describes new results from the 750 mg MAD cohort, the highest MAD dose level in this now-completed study.<br \/><b>Methods. <\/b>Phase 1, single-center, prospective, randomized, double-blind, placebo-controlled study of 9 SAD and 4 MAD cohorts of PRTX007 administered QOD orally to healthy adult participants. Primary objectives were safety and tolerability. Secondary objectives were evaluation of pharmacokinetics (PK) and pharmacodynamics. In total, 104 of the 130 participants in this study received study drug.<br \/><b>Results. <\/b>AEs were limited to non-dose-related mild headache, minor dose-related increases in ALT (&#60;2X ULN) that rapidly resolved, and mild-moderate fever that were transiently observed in 1 of 8 participants. The PKs of PRTX007 and PRX034 are well-behaved with exposure increasing proportionally to PRTX007 dose without accumulation upon repeated dosing (mean PRX034 AUC (hr*ng\/ml) on D1: 13,432; D13: 13,796). Coordinated expression of interferon-stimulated genes and genes known to be related to TLR7 agonism were observed in immune cells in blood in all participants. Increases in IL-1RA, MCP-1 and IP10 in plasma were also observed. IL-6, TNF&#945; and IL- 1&#946; remained essentially unchanged from pretreatment levels. The proportion of CD8<sup>+<\/sup> T cells and NK cells, with significant expression of the proliferation marker Ki67 and activation marker CD38, increased markedly from pretreatment to end of dosing in all participants. Ki67<sup>+<\/sup> expressing CD8<sup>+<\/sup> T cells increased from 1.1% to 9.8% and Ki67<sup>+<\/sup> expressing NK cells increased from 3.6% to 10.3% during the two-week period of drug administration. CD38<sup>+<\/sup> CD8<sup>+<\/sup> T cells increased from 11.8% to 21.9% and CD38<sup>+<\/sup> NK cells increased from 59.4% to 80.0% during the corresponding period.<br \/><b>Conclusion. <\/b>PRTX007 demonstrated a favorable safety profile in all SAD and MAD cohorts. In the 750 mg MAD cohort, activation of the innate and adaptive immune response including important effector cell populations were observed without systemic increases in proinflammatory factors.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Immunotherapy,TLR7,Natural killer cells,Innate immunity,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><i>Charlotte R. Lemech<\/i><\/presenter>, <presenter><i>Christopher Argent<\/i><\/presenter>, <presenter><u><i>Curtis L. Scribner<\/i><\/u><\/presenter>, <presenter><i>Andrew Sharabi<\/i><\/presenter>, <presenter><i>Richard Daniels<\/i><\/presenter>, <presenter><i>James R. Appleman<\/i><\/presenter>. Scientia Clinical Research Ltd, Randwick, Australia, Curtis L. Scribner, Oakland, CA, University of California San Diego, San Diego, CA, Primmune Therapeutics, Carlsbad, CA","CSlideId":"","ControlKey":"01bb8f5f-78d3-4b6d-9049-98e76d57386a","ControlNumber":"9564","DisclosureBlock":"<b>&nbsp;C. R. Lemech, <\/b> <br><b>Primmune Therapeutics<\/b> Independent Contractor. <br><b>C. Argent, <\/b> <br><b>Primmune Therapeutics<\/b> Independent Contractor. <br><b>C. L. Scribner, <\/b> <br><b>Primmune Therapeutics<\/b> Independent Contractor. <br><b>A. Sharabi, <\/b> <br><b>Primmune Therapeutics<\/b> Independent Contractor. <br><b>R. Daniels, <\/b> <br><b>Primmune Therapeutics<\/b> Employment. <br><b>J. R. Appleman, <\/b> <br><b>Primmune Therapeutics<\/b> Employment, Stock, Stock Option.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10318","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"12","PosterboardNumber":"12","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT180","PresenterBiography":null,"PresenterDisplayName":"Curtis Scribner, MD","PresenterKey":"bc0bc450-553f-4f45-ada0-b0db8b6bcdcb","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT180. Activation of innate and adaptive immune response with a clinical stage TLR7 agonist prodrug PRTX007","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"732","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Activation of innate and adaptive immune response with a clinical stage TLR7 agonist prodrug PRTX007","Topics":null,"cSlideId":""},{"Abstract":"Background: SHR-A1921 is a novel ADC composed of a humanized anti-trophoblast cell-surface antigen 2 (TROP-2) IgG1 monoclonal antibody attached to a DNA topoisomerase I inhibitor via a tetrapeptide-based cleavable linker. Herein, we present the preliminary clinical results of the FIH study of SHR-A1921.<br \/>Methods: This is a multi-center, open-label, phase 1 trial (Clinicaltrials.gov, NCT05154604) consisted of dose-escalation, dose-expansion and efficacy-expansion phases. Patients with advanced solid tumors who had failed standard therapy were enrolled. In the dose-escalation phase, SHR-A1921 was planned to be administered from 1.5 mg\/kg to 12.0 mg\/kg (Q3W, iv) in an i3+3 design, with accelerated titration used for the starting dose; in the dose-expansion phase, additional patients (up to 20-30 per dose level) were enrolled to 2-3 selected tolerable dose levels. The primary objectives were to evaluate the safety and tolerability of SHR-A1921 and to determine the maximum tolerated dose (MTD) and\/or recommended phase 2 dose.<br \/>Results: As of Oct 21. 2022, 38 enrolled patients were included for analysis: 18 enrolled during dose-escalation (1.5 mg\/kg, n=1; 3.0 mg\/kg, n=4; 4.0 mg\/kg, n=8; 6.0 mg\/kg, n=5) and 20 during dose-expansion (3.0 mg\/kg). 71.1% (27\/38) were driver gene-negative non-small cell lung cancer (NSCLC) patients who had previously received platinum-based chemotherapy and anti-PD-(L)1 antibody. 4 patients reported dose-limiting toxicities, with all being grade 3 stomatitis (6.0 mg\/kg, n=3; 4.0 mg\/kg, n=1). The MTD was established as 4.0 mg\/kg. Across all dose cohorts, the most common treatment-related adverse events (TRAEs; &#8805;30%) were nausea (71.1%), stomatitis (65.8%), anemia (42.1%), vomiting, decreased appetite, decreased weight, and rash (36.8% each). Grade &#8805;3 TRAEs occurred in 12 patients (31.6%); of these, the most common was stomatitis (n=7, 18.4%), and all other events were reported in &#8804;2 patients. No patients discontinued study treatment due to TRAEs. As of cut-off date, 10 patients (NSCLC, n=5; triple-negative breast cancer, n=2; ampullary cancer, n=2; ovarian cancer, n=1) had partial response: 4 confirmed and 6 requiring further confirmation. The objective response rate was 33.3% (10\/30; 95% CI 17.3-52.8) and disease control rate was 80.0% (24\/30; 95% CI 61.4-92.3) in evaluable patients.<br \/>Conclusion:<b> <\/b>SHR-A1921 showed a manageable safety profile and promising anti-tumor activity in patients with pretreated advanced cancer. The trial is ongoing to assess SHR-A1921 at different dosing frequency and the efficacy in selected cancer types.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Antibody-drug conjugate (ADC),Trop-2,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Jie Wang<\/i><\/u><\/presenter>, <presenter><i>Lin Wu<\/i><\/presenter>, <presenter><i>Zhengbo Song<\/i><\/presenter>, <presenter><i>Xingya Li<\/i><\/presenter>, <presenter><i>Caigang Liu<\/i><\/presenter>, <presenter><i>Tianshu Liu<\/i><\/presenter>, <presenter><i>Yiwen Wu<\/i><\/presenter>, <presenter><i>Ze Zhang<\/i><\/presenter>, <presenter><i>Shuni Wang<\/i><\/presenter>. Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences  Peking Union Medical College, Beijing, China, Department of Internal Medicine, Hunan Cancer Hospital, Changsha, China, Phase I Clinical Trial Ward, Zhejiang Cancer Hospital, Hangzhou, China, Second Ward, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, Cancer Research Center, Shengjing Hospital of China Medical University, Shenyang, China, Department of Oncology, Zhongshan Hospital Fudan University, Shanghai, China, Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co. Ltd, Shanghai, China","CSlideId":"","ControlKey":"b9f688ef-1d90-4b0b-b11d-2d3c39fa62c7","ControlNumber":"9608","DisclosureBlock":"&nbsp;<b>J. Wang, <\/b> None..<br><b>L. Wu, <\/b> None..<br><b>Z. Song, <\/b> None..<br><b>X. Li, <\/b> None..<br><b>C. Liu, <\/b> None..<br><b>T. Liu, <\/b> None.&nbsp;<br><b>Y. Wu, <\/b> <br><b>Jiangsu Hengrui Pharmaceuticals Co. Ltd<\/b> Employment. <br><b>Z. Zhang, <\/b> <br><b>Jiangsu Hengrui Pharmaceuticals Co. Ltd<\/b> Employment. <br><b>S. Wang, <\/b> <br><b>Jiangsu Hengrui Pharmaceuticals Co. Ltd<\/b> Employment.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10319","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"13","PosterboardNumber":"13","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT181","PresenterBiography":null,"PresenterDisplayName":"Xiuzhi Wu","PresenterKey":"6b0d90dd-f5cd-4b74-8b9d-90278457ab77","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT181. A first-in-human (FIH) phase 1 study of SHR-A1921, a TROP-2 targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"732","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A first-in-human (FIH) phase 1 study of SHR-A1921, a TROP-2 targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Purpose: Many cancers suffer from dysfunctional redox status. MTH1 protects cancer cells from oxidative DNA damage by preventing incorporation of oxidized nucleotides. OXC-101 (Karonudib) is a dual-action mitotic disruptor and MTH1 inhibitor, preventing exit from mitosis and sanitation of oxidative damage to DNA subunits in cancer cells. MASTIFF, (<u>M<\/u>TH1, <u>A<\/u> Phase I, <u>S<\/u>tudy on <u>T<\/u>umors <u>I<\/u>nhibition, <u>F<\/u>irst in Human, <u>F<\/u>irst in Class), is a first- in- human phase 1 study, with the primary aim to assess safety, tolerability, and pharmacokinetics (PK) of OXC-101 in patients (pts) with advanced solid malignant tumors (NCT03036228).<br \/>Methods: Phase 1a study with 3+3 design and intra-patient dose escalation. New cohorts were opened following review of safety and PK data by the safety data monitoring board after the first treatment cycle of 4 weeks (w). All patients had progressive stage IV disease with no treatment options in SOC at inclusion. Radiological tumor response evaluation (RECIST 1.1) was performed 8w of the first 24w, 12w thereafter. The first 29 patients (cohort 1-10) obtained an oral solution. From cohort 11 pts obtained 100mg tablets.<br \/>Results: 50 subjects (50% female, 50% male) were enrolled at 16 dose levels of OXC-101 at varying posology: 25-900 mg BID, 800-1000mg QD; every second day, once or twice weekly. Mean age was 52 years (range:20-74). 92% of pts had received previous chemotherapy (mean: 5 lines, range:0-34), 18% endocrine therapy and 52% other therapies (incl immunotherapy). OXC-101 was generally well tolerated and with manageable toxicity for dose levels for an average of 121 days (range:2-513 days), and 43\/50 subjects discontinued due to disease progression. A total of 20 SAEs were reported: 8 SAEs in 7 subjects were considered related\/possibly related to OXC-101 and included pneumonia (3\/8), febrile neutropenia (2\/8), ileus (1\/8), unspecified infection (1\/8) and fever (1\/8). There were 14 dose-limiting toxicities (DLTs) reported in 7 subjects. At 510mg every second day (1785mg weekly) 2\/5 subjects reported G4 neutropenia; at 500mg BID\/1000mg QD, twice per week (2000 mg weekly) 2\/9 subjects reported G4 neutropenia; at 900mg BID, once weekly (1800 mg weekly) 3\/3 subjects reported decrease in white blood count incl. neutropenia. PK was robust and predictable with good exposure correlation between solution and tablet formulation, with an average half-life of 10 hrs in plasma. 15\/49 (31% ) of the subjects showed stable disease at first radiological evaluation. One subject had stable disease during 73 weeks on OXC-101 treatment. IHC and western blot analysis on tumor biopsies confirmed mechanism of action. A dose of 900mg (500mg mane, 400mg nocte) twice a week (total weekly dose 1800mg) was determined as the Recommended Phase 2 Dose (RP2D). This will be further explored in tumor specific cohorts.<br \/>Conclusion: OXC-101 has a favorable safety profile with an RP2D of 900mg twice a week.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"DNA damage response,Microtubules,Cancer therapy,MTH1,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><i>Jeffrey Yachnin<\/i><\/presenter>, <presenter><i>Lars Ny<\/i><\/presenter>, <presenter><i>Teresa Sandvall<\/i><\/presenter>, <presenter><i>Kumar Sanjiv<\/i><\/presenter>, <presenter><i>Martin Scobie<\/i><\/presenter>, <presenter><i>Bjrn Platzack<\/i><\/presenter>, <presenter><i>Pawel Barancewski<\/i><\/presenter>, <presenter><i>Olof Breuer<\/i><\/presenter>, <presenter><i>Vassilis Gorgoulis<\/i><\/presenter>, <presenter><i>Ioannis S. Pateras<\/i><\/presenter>, <presenter><i>Maria Klockare<\/i><\/presenter>, <presenter><u><i>Austin Smith<\/i><\/u><\/presenter>, <presenter><i>Ulrika Warpman Berglund<\/i><\/presenter>, <presenter><i>Thomas Helleday<\/i><\/presenter>. Karolinska University Hospital, Stockholm, Sweden, Sahlgrenska University Hospital, Gothenburg, Sweden, Oxcia AB, Stockholm, Sweden, Karolinska Insitutet, Stockholm, Sweden, Scantox, Stockholm, Sweden, ScilifeLab DDD, Uppsala University, Uppsala, Sweden, National and Kapodistrian University of Athen, Athen, Greece, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece","CSlideId":"","ControlKey":"e30f9917-c374-48b5-a8dd-8341db9b162d","ControlNumber":"9627","DisclosureBlock":"&nbsp;<b>J. Yachnin, <\/b> None..<br><b>L. Ny, <\/b> None.&nbsp;<br><b>T. Sandvall, <\/b> <br><b>Oxcia AB<\/b> Stock. <br><b>K. Sanjiv, <\/b> <br><b>Oxcia AB<\/b> Stock. <br><b>M. Scobie, <\/b> <br><b>Oxcia AB<\/b> Employment, Stock, Patent. <br><b>B. Platzack, <\/b> <br><b>Scantox<\/b> Employment. <br><b>P. Barancewski, <\/b> <br><b>Oxcia AB<\/b> Stock. <br><b>O. Breuer, <\/b> <br><b>Oxia AB<\/b> Independent Contractor. <br><b>V. Gorgoulis, <\/b> <br><b>Helleday Foundation for Medical Research<\/b> Grant\/Contract. <br><b>I. S. Pateras, <\/b> <br><b>Helleday foundation for medical research<\/b> Grant\/Contract. <br><b>M. Klockare, <\/b> <br><b>Oxcia AB<\/b> Employment. <br><b>A. Smith, <\/b> <br><b>Oxcia AB<\/b> Employment. <br><b>U. Warpman Berglund, <\/b> <br><b>Oxcia AB<\/b> Employment, Stock. <br><b>T. Helleday, <\/b> <br><b>Oxcia AB<\/b> Stock, Patent.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10320","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"14","PosterboardNumber":"14","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT182","PresenterBiography":null,"PresenterDisplayName":"Austin Smith, MD","PresenterKey":"c33e9593-6cc1-4d7b-b619-c786ee5e6c8d","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT182. OXC-101 shows favorable safety profile in first in human phase 1 trial in patients with advanced solid cancer","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"732","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"OXC-101 shows favorable safety profile in first in human phase 1 trial in patients with advanced solid cancer","Topics":null,"cSlideId":""},{"Abstract":"Background: SHP2 is an oncogenic tyrosine phosphatase that transduces receptor tyrosine kinase signaling to the RAS\/MAPK pathway via its phosphatase-mediated regulation of guanine nucleotide exchange factors. ERAS-601 is a potent, selective, and orally bioavailable allosteric inhibitor of SHP2. In combination with cetuximab, an antibody that targets epidermal growth factor receptor (EGFR), ERAS-601 has demonstrated robust nonclinical activity in human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) and RAS\/RAF wild-type colorectal cancer (CRC) tumors.<br \/>Method: FLAGSHP-1 is the first-in-human trial of ERAS-601 administered as monotherapy and in combination with other cancer therapies in patients with advanced or metastatic solid tumors. The primary objectives are to characterize the safety profile, determine the maximum tolerated dose (MTD)\/recommended dose (RD), and characterize the pharmacokinetics (PK) profile of ERAS-601 as a monotherapy and in combination with other cancer therapies. Secondary objectives include tolerability and antitumor activity in solid tumors. Presented here are results from the combination dose escalation cohorts in which patients received ERAS-601 twice a day for three weeks followed by a one-week break (BID 3\/1) in combination with cetuximab (500mg\/m<sup>2<\/sup>) administered every 2 weeks (Q2W) on a 28-day cycle.<br \/>Results: As of October 31, 2022, a total of 15 patients with previously treated advanced or metastatic solid tumors received ERAS-601 BID 3\/1 at the following dose levels: 20 mg BID 3\/1 (n=4), 40 mg BID 3\/1 (n=8), or 60 mg BID 3\/1 (n=3) in combination with cetuximab. Combination therapy MTD was determined&#8203; to be 40 mg BID 3\/1. ERAS-601 Treatment Related Adverse Events (TRAEs) at or below the MTD were all Grade 1 and 2. TRAEs occurring in &#8805;20% of patients included diarrhea (27%), AST increase (27%), ALT increase (20%), dermatitis acneiform (20%). Grade &#8805;3 TRAEs included Grade 4 hypokalaemia, Grade 3 diarrhea, platelet count decreased anemia (each 7%); high grade TRAEs were only observed at 60 mg BID 3\/1 (above the MTD). Dose limiting toxicities (DLTs) were only observed at the 60mg BID 3\/1 dose levels and included Grade 3 platelet count decreased (n=1) and Grade 4 hypokalemia (n=1). Pharmacokinetics of ERAS-601 and cetuximab in combination were generally comparable to historical monotherapy PK values, suggesting lack of drug-drug interaction. The evaluation of clinical activity is still ongoing.<br \/>Conclusions: ERAS-601 in combination with cetuximab in patients with previously treated advanced or metastatic solid tumors shows promising preliminary safety and tolerability with reversible and manageable TRAEs. Further evaluation in relevant tumor types are ongoing.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Phase I,SHP2,Cetuximab,PTPN11,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Meredith McKean<\/i><\/u><\/presenter>, <presenter><i>Ezra Rosen<\/i><\/presenter>, <presenter><i>Minal Barve<\/i><\/presenter>, <presenter><i>Tarek Meniawy<\/i><\/presenter>, <presenter><i>Judy Wang<\/i><\/presenter>, <presenter><i>David S. Hong<\/i><\/presenter>, <presenter><i>Jennifer Yang<\/i><\/presenter>, <presenter><i>Zhengrong Li<\/i><\/presenter>, <presenter><i>Roxana Picard<\/i><\/presenter>, <presenter><i>Les Brail<\/i><\/presenter>, <presenter><i>Daniela Vecchio<\/i><\/presenter>, <presenter><i>Thomas John<\/i><\/presenter>, <presenter><i>Ezra Cohen<\/i><\/presenter>, <presenter><i>Gregory Obara<\/i><\/presenter>, <presenter><i>Aparna Parikh<\/i><\/presenter>. Sarah Cannon Research Institute, Nashville, TN, Memorial Sloan Kettering Cancer Center, New York, NY, Mary Crowley Cancer Research, Dallas, TX, Linear Clinical Research and University of Western Australia, Nedlands, Australia, Florida Cancers Specialists\/Sarah Cannon Research Institute, Sarasota, FL, MD Anderson, Houston, TX, Erasca, Inc., San Diego, CA, Peter MacCallum Cancer Centre, Melbourne, Australia, University of California, San Diego, CA, Comprehensive Cancer Center of Nevada, Las Vegas, NV, Massachusetts General Hospital, Boston, MA","CSlideId":"","ControlKey":"b6523364-8f72-4d7b-b6d1-0c9f2bb97370","ControlNumber":"9699","DisclosureBlock":"<b>&nbsp;M. McKean, <\/b> <br><b>Array BioPharma<\/b> Other, Advisory Board. <br><b>AstraZeneca<\/b> Advisory Board. <br><b>MedPage Today<\/b> Advisory Board. <br><b>Pfizer<\/b> Advisory Board. <br><b>Regeneron Pharmaceuticals<\/b> Advisory Board.<br><b>E. Rosen, <\/b> None..<br><b>M. Barve, <\/b> None..<br><b>T. Meniawy, <\/b> None.&nbsp;<br><b>J. Wang, <\/b> <br><b>BioNTech<\/b> Other, Advisory Board. <br><b>Stemline\/Menarini<\/b> Other, Advisory Board. <br><b>Janssen<\/b> Other, Advisory Board. <br><b>Kanaph<\/b> Other, Advisory Board. <br><b>D. S. Hong, <\/b> <br><b>Bayer<\/b> Travel, Other, Accommodations, Expenses, Advisory. <br><b>Genmab<\/b> Travel, Other, Accommodations, Expenses. <br><b>Telperian<\/b> Travel, Accommodations, Expenses, Founder, Advisor. <br><b>Erasca<\/b> Other, consulting. <br><b>Abbvie<\/b> Other, consulting. <br><b>Acuta<\/b> Other, consulting. <br><b>Adaptimmune<\/b> Other, consulting. <br><b>Amgen<\/b> Other, consulting. <br><b>BridgeBio,<\/b> Other, consulting. <br><b>F. Hoffmann-La Roche<\/b> Other, consulting. <br><b>Genentech<\/b> Other, consulting. <br><b>Gennao Bio<\/b> Other, consulting. <br><b>Gilead<\/b> Other, consulting. <br><b>Precision Oncology<\/b> Other, consulting. <br><b>Immunogenesis<\/b> Other, consulting. <br><b>Janssen<\/b> consulting. <br><b>Oncologia<\/b> Other, consulting. <br><b>Pfizer<\/b> Other, consulting. <br><b>Molecular Match<\/b> Other, Advisor. <br><b>OncoResponse<\/b> Founder, Advisor. <br><b>J. Yang, <\/b> <br><b>Erasca<\/b> Employment, Stock, Stock Option. <br><b>Z. Li, <\/b> <br><b>Erasca<\/b> Employment, Stock, Stock Option. <br><b>R. Picard, <\/b> <br><b>Erasca<\/b> Employment, Stock, Stock Option. <br><b>L. Brail, <\/b> <br><b>Erasca<\/b> Employment, Stock, Stock Option. <br><b>Eli Lilly<\/b> Stock. <br><b>D. Vecchio, <\/b> <br><b>Erasca<\/b> Employment, Stock, Stock Option.<br><b>T. John, <\/b> None..<br><b>E. Cohen, <\/b> None..<br><b>G. Obara, <\/b> None.&nbsp;<br><b>A. Parikh, <\/b> <br><b>C2i genomics<\/b> Stock, Equity. <br><b>Eli Lilly<\/b> Other, advisor\/consultant. <br><b>Pfizer<\/b> Other, advisor\/consultant. <br><b>Inivata<\/b> Other, advisor\/consultant. <br><b>Biofidelity<\/b> Other, advisor\/consultant. <br><b>Natera<\/b> Other, advisor\/consultant. <br><b>Checkmate Pharmaceuticals<\/b> Other, advisor\/consultant. <br><b>FMI<\/b> Other, advisor\/consultant. <br><b>Guardant<\/b> Other, advisor\/consultant. <br><b>Taiho<\/b> Other, advisor\/consultant. <br><b>Abbvie<\/b> Other, advisor\/consultant. <br><b>Bayer<\/b> advisor\/consultant.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10322","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"15","PosterboardNumber":"16","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT184","PresenterBiography":null,"PresenterDisplayName":"Meredith McKean, MD;MPH","PresenterKey":"fa86d407-1936-47fc-a466-1342a703b303","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT184. Preliminary dose escalation results of ERAS-601 in combination with cetuximab in FLAGSHP-1: a phase I study of ERAS-601, a potent and selective SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"732","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Preliminary dose escalation results of ERAS-601 in combination with cetuximab in FLAGSHP-1: a phase I study of ERAS-601, a potent and selective SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Background: BYON3521 is a novel c-MET targeting antibody-drug conjugate (ADC) with a cleavable linker-duocarmycin (vc-<i>seco<\/i>-DUBA) payload that causes irreversible alkylation of DNA in tumor cells. BYON3521 has demonstrated potent and selective killing of c-MET expressing tumor cells in preclinical models, even at low c-MET expression levels. In addition, <i>in vitro<\/i> studies showed that the active toxin can passively permeate the cell membrane and kill neighboring, c-MET negative cells as a bystander effect.<br \/>Methods: Patients with previously treated progressive locally advanced or metastatic solid tumors, c-MET positive membrane staining by immunohistochemistry and\/or <i>MET-<\/i>amplified by dual <i>in situ<\/i> hybridization and\/or known activating <i>MET<\/i>-mutation (excluding exon14m), ECOG performance status 0-1 and adequate organ function are eligible for the dose-escalation part of this first-in-human trial (ClinicalTrials.gov identifier: NCT05323045). An adaptive approach using the Continual Reassessment Method of Neuenschwander (N-CRM model) is used to evaluate the safety of BYON3521 and to determine the maximum tolerated dose (MTD) and recommended dose for expansion (RDE). BYON3521 is administered intravenously every three weeks until tumor progression or unacceptable toxicity.<br \/>Results: Up to 01 January 2023, 8 patients (1F, 7M, median age 61 yrs) were enrolled. Tumor types were: 4 colorectal cancer, 1 NSCLC, 1 renal cell carcinoma, 1 esophageal cancer and 1 pancreatic cancer. One patient received 0.8 mg\/kg, three patients each 1.6 and 3.2 mg\/kg and one patient received 4.8 mg\/kg. So far, no grade 3 or 4 related adverse events and no dose-limiting toxicities (DLTs) occurred. Most commonly observed related AEs were decreased appetite\/weight, fatigue, abdominal pain, back pain, vomiting and chills. Typical ADC associated AEs as keratitis and pneumonitis have not been observed so far. Stable disease was the best response observed in 2 patients at a dose of 3.2 mg\/kg. Human PK was in line with predicted preclinical in vivo PK.<br \/>Conclusions: To date, BYON3521 is well-tolerated with no DLTs at the investigated dose levels. Patient enrollment is ongoing and updated safety, efficacy and pharmacokinetic data will be presented. After the dose-escalation phase the trial will continue with expanded cohorts of patients with specific c-MET expressing cancer types.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"c-Met,Antibody-drug conjugate (ADC),BYON3521,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>N. Kotecki<\/i><\/u><\/presenter>, <presenter><i>C.M.L. Van Herpen<\/i><\/presenter>, <presenter><i>C. Curigliano<\/i><\/presenter>, <presenter><i>M. Hendriks<\/i><\/presenter>, <presenter><i>T C. M. Vermaas<\/i><\/presenter>, <presenter><i>L. Corrigan<\/i><\/presenter>, <presenter><i>C. Belli<\/i><\/presenter>, <presenter><i>C. Jungels<\/i><\/presenter>, <presenter><i>I.M.E. Desar<\/i><\/presenter>, <presenter><i>N.P. Koper<\/i><\/presenter>, <presenter><i>J.H.M. Schellens<\/i><\/presenter>, <presenter><i>U. Banerji<\/i><\/presenter>. Medical Oncology Clinic, Institut Jules Bordet - Universit Libre de Bruxelles, Brussels, Belgium, Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands, European institute of Oncology, IRCCS  University of Milano, Milan, Italy, Byondis B.V., Nijmegen, Netherlands, Drug Development Unit, The Institute of Cancer Research and The Royal Marsden Hospital, London, United Kingdom, Division of New Drugs and Early Development for Innovative Therapies, European institute of Oncology, Milan, Italy","CSlideId":"","ControlKey":"5027fa6b-513f-423a-a623-7ecc78afb9fb","ControlNumber":"9797","DisclosureBlock":"&nbsp;<b>N. Kotecki, <\/b> None..<br><b>C. van Herpen, <\/b> None.&nbsp;<br><b>C. Curigliano, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract, Other, Invited Speaker, Advisory Board. <br><b>BMS<\/b> Grant\/Contract, Other, Advisory board. <br><b>Celcuity<\/b> Other, Advisory Board. <br><b>Daiichi Sankyo<\/b> Grant\/Contract, Other, Invited Speaker, advisory board. <br><b>Exact Sciences<\/b> Other, Advisory Board. <br><b>Lilly<\/b> Advisory Board. <br><b>Merck<\/b> Grant\/Contract, Other, Advisory Board. <br><b>Novartis<\/b> Grant\/Contract, Other, Invited speaker. <br><b>Pfizer<\/b> Other, Invited speaker, Advisory Board, Writing engagement. <br><b>Roche<\/b> Grant\/Contract, Other, Advisory Board, Invited speaker. <br><b>Veracyte<\/b> Other, Advisory Board. <br><b>Ellipsis<\/b> Other, Advisory Board. <br><b>Astellas<\/b> Grant\/Contract. <br><b>Blueprint Medicine<\/b> Grant\/Contract. <br><b>Kymab<\/b> Grant\/Contract. <br><b>Philogen<\/b> Grant\/Contract. <br><b>Relay Therapeutics<\/b> Grant\/Contract. <br><b>Sanofi<\/b> Grant\/Contract. <br><b>M. Hendriks, <\/b> <br><b>Byondis B.V.<\/b> Employment.<br><b>L. Corrigan, <\/b> None..<br><b>C. Belli, <\/b> None..<br><b>C. Jungels, <\/b> None..<br><b>I. Desar, <\/b> None.&nbsp;<br><b>N. Koper, <\/b> <br><b>Byondis B.V.<\/b> Employment. <br><b>J. Schellens, <\/b> <br><b>Byondis B.V.<\/b> Employment. <br><b>Modra Pharmaceuticals<\/b> Employment, Stock, Patent. <br><b>U. Banerji, <\/b> <br><b>The Institute of Cancer Research<\/b> Employment. <br><b>Verastem Oncology<\/b> Grant\/Contract. <br><b>Carrick Therapeutics<\/b> Grant\/Contract. <br><b>Chugai<\/b> Grant\/Contract. <br><b>Carrick Therapeutics<\/b> Other, Advisory Board. <br><b>Pegasy<\/b> Other, Advisory Board.","End":"4\/18\/2023 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"10323","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"16","PosterboardNumber":"17","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT185","PresenterBiography":null,"PresenterDisplayName":"N. Kotecki, MD","PresenterKey":"ae25e58a-425a-4c56-bb44-977e7b47f2f5","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT185. First in human dose-escalation trial with the c-MET targeting antibody-drug conjugate BYON3521","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  9:00AM","SessionId":"732","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 2","ShowChatLink":"false","Start":"4\/18\/2023 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"First in human dose-escalation trial with the c-MET targeting antibody-drug conjugate BYON3521","Topics":null,"cSlideId":""}]